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Abstract 
Over 30% of patients with renal cell carcinoma (RCC) present with metastases, with median 
survival of 2 years. Kidney injury molecule 1 (KIM-1) is a cell-surface glycoprotein expressed 
by >90% of RCC tumours. Preliminary data mined from The Cancer Genome Atlas RNA-
sequencing database indicates that KIM-1 overexpression predicts overall survival in patients. 
Here we sought to determine if tumour KIM-1 plays a role in RCC cell extravasation and 
metastasis to the lungs. In vitro invasion and in vivo metastasis assays were performed to 
investigate the metastatic potential of KIM-1-expressing cells, and RNA-seq was conducted to 
identify differentially expressed genes between KIM-1+ and KIM-1neg cells.  
Invasion was significantly decreased in vitro in both murine and human RCC cells that 
expressed KIM-1. We concluded that KIM-1 inhibits RCC extravasation and metastasis to the 
lungs, independent of adaptive immunity. RNA-seq analysis provided putative downstream 
effectors of KIM-1. 
 
Lay Summary 
Metastasis is often the deadliest aspect of cancer and is characterized by the secondary spread 
of cancer cells to distant sites of the body from the primary tumour. Over a third of patients 
with renal cell carcinoma (RCC) - the most common form of kidney cancer - present with 
metastases at the time of diagnosis. Kidney injury molecule 1 (KIM-1) is a cell-surface protein 
expressed by >90% of RCC tumours. Preliminary data from our lab indicates that KIM-1 
overexpression predicts overall survival in patients. Here we sought to determine if tumour 
KIM-1 plays a role in RCC metastasis to the lungs - the most common site of metastasis in 
RCC. The metastatic potential of KIM-1-expressing cells was investigated, and the differences 
in gene expression between KIM-1+ and KIM-1neg cells were analyzed. 
We concluded that KIM-1 inhibits RCC invasion and metastasis to the lungs, independent of 
the adaptive immune system. RNA-sequencing analysis of the genes provided putative 
downstream effectors of KIM-1, which could serve as novel therapeutic targets for the 
treatment of metastatic RCC. 
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Chapter 1  
1 Introduction 
1.1 Cancer 
Cancer affects over 18 million people worldwide and is the second leading cause of death 
globally. An increase in its incidence is also evident, and can be attributed to various risk 
factors such as environment, poor diet, and inadequate physical activity (Ferlay, 
Soerjomataram et al. 2015). In 2012 alone, GLOBOCAN estimated 14.1 million new cases 
of cancer, and 8.2 million deaths due to cancer. In Canada, an estimated 2 in 5 Canadians 
will develop cancer in their lifetime, and 1 in 4 will die from their disease (Canadian Cancer 
Society 2015). Cancer is characterized as an uncontrolled proliferation and spread of 
abnormal cells, which may lead to death (American Cancer Society 2016). Metastasis is 
characterized by the spread of cancer cells from the primary tumour to distant tissues and 
organs, and the establishment of a tumour at the secondary site (Fidler 2003). Metastases 
are the most severe aspect of cancer, as they are the cause of the majority of deaths in 
cancer patients. One of the most prominent barriers to the treatment of metastatic cancer is 
the heterogeneity of cancer cells within the metastatic focus compared to the primary 
tumour (Fidler 2003).  
Hanahan and Weinberg have proposed that there are six characteristics that are essential 
for the development and progression of all cancers, which they have termed the hallmarks 
of cancer (Figure 1) (Hanahan and Weinberg 2011). Together, these six hallmarks allow 
for the growth and dissemination of tumours: sustaining proliferative signaling, evading 
growth suppressors, inducing angiogenesis, resisting cell death, enabling replicative 
immortality, and activating invasion and metastasis. In recent years, they have suggested 
the addition of two emerging hallmarks: reprogramming of energy metabolism, and 
immune evasion. In addition to the hallmark characteristics, Hanahan and Weinberg have 
posited that enabling characteristics such as genomic instability and tumour-promoting 
inflammation are underlying factors that lead to the development of hallmark 
characteristics.  
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Research into the enigmatic steps of the invasion-metastasis cascade in recent years have 
yielded a greater understanding on this critical step of cancer progression. Technological 
advances have provided newer tools and models to investigate regulatory genes and 
pathways involved in invasion and metastasis and shed light on what was previously poorly 
understood. 
 
 
 
Figure 1. The hallmarks of cancer 
The six hallmarks of cancer first posited by Hanahan and Weinberg in 2000. These 
hallmarks are necessary and essential capabilities that enable tumour growth and metastatic 
dissemination. Adapted with permission from (Hanahan and Weinberg 2011).     
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1.1.1 Invasion and Metastasis 
Metastasis is a complex process, requiring the multi-step succession of events from the 
development of the primary tumour, detachment and degradation of the ECM, intravasation 
into the circulation, adhesion to the blood vessel wall, and finally extravasation into the 
secondary tissue (Figure 2). Invasion and extravasation are the crucial and penultimate 
steps in the spread of cancers.  
 
 
Figure 2. Steps in the process of metastasis 
Metastasis is a complex process that requires multiple steps to occur in succession. Cells 
that successfully detach and enter the vasculature must survive various physical stressors 
before arresting on the endothelium at distal sites. The ability for cancer cells to extravasate 
is essential for the dissemination of cancer cells. Adapted with permission from (Wirtz, 
Konstantopoulos et al. 2011). 
 
1.1.2 Epithelial-mesenchymal-transition and Anoikis 
One critically important process during the dissemination of carcinomas is the process of 
epithelial-mesenchymal-transition (EMT) (Cao, Livas et al. 2016). EMT confers migratory 
and invasive properties upon cancer cells, as well as the ability to degrade the extracellular 
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matrix (ECM), allowing them to leave the primary tumour site and enter the vasculature 
(Lambert, Pattabiraman et al. 2017). Once cancer cells enter the circulation, they must 
overcome enormous physiological stressors before they can establish a metastatic focus at 
a distant site.  Disseminated cancer cells must be able to resist physical stressors such as 
anoikis – a form of apoptosis due to detachment from the extracellular matrix – as well as 
shear stress (Lambert, Pattabiraman et al. 2017). Anoikis is a tumour suppressing 
mechanism that induces apoptosis in normal epithelial and endothelial cells that lose 
contact with the ECM and suppresses proliferation of transformed cells at ectopic sites 
(Rennebeck, Martelli et al. 2005). Resistance to anoikis is therefore essential to the survival 
and migration of malignant cells in the vasculature. Anoikis resistance in cancer cells is 
coupled with mechanisms that promote invasiveness which allow disseminated cells to 
migrate to distal sites and establish metastases (Zhu, Sanchez-Sweatman et al. 2001, 
Sakamoto, McCann et al. 2010). Along with the physical impediments, cancer cells will 
encounter a plethora of cell types; among them, platelets, neutrophils, and NK cells, which 
may serve to facilitate their passage or swiftly end their journey (Lambert, Pattabiraman et 
al. 2017).  
1.1.3 Arrest and Extravasation 
One of the final obstacles malignant cells must overcome is the process of trans-endothelial 
migration (TEM). Cancer cells must gain the ability to extravasate out of the bloodstream 
and into the secondary tissue sites. Often, this occurs in small capillaries where the cancer 
cells are physically confined to narrow luminal spaces, where they form stable interactions 
with adhesion molecules on endothelial cells (Reymond, d'Agua et al. 2013). Studies have 
shown that cancer cells may roll along the endothelium until stable adhesions form between 
tumour cells and endothelial cells, by action of selectins, cadherins, and integrins (Miles, 
Pruitt et al. 2008, Stoletov, Kato et al. 2010). Integrins are a group of  cell-surface  proteins 
that enable cells to attach to the extracellular matrix (ECM), and sense whether adhesion 
has occurred; β1-integrins specifically, have been shown to be crucial for mediating the 
dynamic remodeling of endothelial cell junctions (Stoletov, Kato et al. 2010), through the 
actions of Rho-GTPases (Miles, Pruitt et al. 2008).  
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1.1.4 Rho-GTPases in Cancer 
Rho-GTPases regulate cytoskeletal changes necessary for TEM by modulating actin 
filament assembly  (Braga, Del Maschio et al. 1999, Miles, Pruitt et al. 2008). Calcium-
dependent cadherin molecules are a family of molecules that contribute to cell-cell 
adhesion. Cadherins line the extracellular domains of epithelial and endothelial cells and 
hold cells together through homophilic interactions (Lozano, Betson et al. 2003). Actin 
reorganization by Rho-GTPases alters the stability of endothelial cell-cell junctions – 
known as adherens junctions – by interacting with the cytoplasmic ends of cadherin 
molecules and disrupting the cell-cell interactions (Miles, Pruitt et al. 2008). Additionally, 
Rho-GTPases may also regulate cancer cell motility through the same process of actin 
reorganization. The disruption of cadherin-mediated adhesion is known to be one of the 
most efficient mechanisms to achieve EMT, and Rho-GTPases have been shown to be 
necessary for the maintenance of said cadherin-mediated adhesions (Braga 2000, Lozano, 
Betson et al. 2003). Disruptions in both cadherin expression and function, as well as 
deregulations in Rho-GTPases are thought to be required for TEM to occur.  
1.1.5 Chemokines in Cancer 
Chemokines also play a major role in invasion and metastasis, through their interactions 
with G protein-coupled receptors (GPCR). It is well understood that certain cancer types 
metastasize to specific secondary sites; prostate cancers preferentially metastasize to the 
bone; lung cancers preferentially metastasize to the bone, liver and brain; breast cancers 
preferentially metastasize to the lung, bone, liver, and brain; pancreatic cancers 
preferentially metastasize to the liver; and kidney cancers preferentially metastasize to the 
lungs, bone, and lymph nodes (Patanaphan, Salazar et al. 1988, Edlund, Sung et al. 2004, 
Hess, Varadhachary et al. 2006, Bianchi, Sun et al. 2012). The seed-and-soil hypothesis 
helps to partly explain these metastatic patterns through the understanding of the 
expression of chemokines and their receptors between target sites and cancer cells. Of all 
the chemokines known, the CXCR4/CXCL12 axis is most often implicated in tumour 
progression, metastasis, and survival (Teicher and Fricker 2010). CXCR4 is an alpha-
chemokine receptor that is normally absent or expressed at low levels, and only 
overexpressed by malignant epithelial cells (Balkwill 2004). It is believed that the 
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expression of CXCL12, also known as stromal-derived-factor-1 (SDF-1), by the target 
endothelium attracts cancer cells expressing its cognate receptor CXCR4 and stimulates 
their extravasation into secondary tissues. Studies have demonstrated the homing effect 
that CXCL12 has on CXCR4+ cancer cells, showing that the CXCR4/CXCL12 axis has no 
effect on adhesion, but significantly enhances tumour cell extravasation (which was 
accompanied by the activation of Rho-GTPases) (Gassmann, Haier et al. 2009, Teicher and 
Fricker 2010). The continued expression of these chemokines acts as a component of the 
“soil” to retain the “seeds” that have made the pilgrimage from their primary tumours, and 
promote angiogenesis, proliferation, and survival (Balkwill 2004, Teicher and Fricker 
2010). 
1.2 Renal Cell Carcinoma  
Kidney cancer is the eighth most common form of cancer, and the twelfth leading cause of 
deaths due to cancer (De, Otterstatter et al. 2014). Renal cell carcinoma (RCC) is the most 
common form and accounts for over 90% of all cases of kidney cancer, with a 5-year 
survival rate of 72% at the time of diagnosis (De, Otterstatter et al. 2014). Depending on 
tumour progression, survival rates can be considerably lower in patients with metastatic 
forms of the disease. These survival rates are drastically reduced in patients diagnosed with 
stage IV of the disease – characterized by the metastasis of the tumour to distant sites – to 
a mere 8% (American Cancer Society 2016). Due to a lack of effective screening tests for 
the early stages of the disease, over 30% of patients present with metastases at the time of 
diagnosis (Canadian Cancer Society 2015). 
1.2.1 Risk Factors and Causes of RCC 
Risk factors for RCC development include smoking, obesity, having first-degree relatives 
with the disease, as well as a genetic mutation of the von Hippel-Lindau (VHL) protein 
(De, Otterstatter et al. 2014). Of the RCC subtypes, the clear cell variant (ccRCC) accounts 
for more than 80% of them (De, Otterstatter et al. 2014). The majority of ccRCCs have a 
loss-of-function mutation in a gene on chromosome 3, which codes for the VHL protein, a 
tumour suppressor known to mediate proteasomal degradation; one of its best known 
targets is the alpha subunit of hypoxia inducible factors (HIF) (Kumar and Gabrilovich 
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2014). An accumulation of HIFs is associated with increased expression of vascular 
endothelial growth factor (VEGF) and other angiogenic factors – conditions typically seen 
in pre-malignant lesions (Kumar and Gabrilovich 2014, Schodel, Grampp et al. 2016). Two 
isoforms of hypoxia-inducible factor alpha exist: HIF-1α and HIF-2α. Unique to ccRCC, 
it has been shown that the two HIFα isoforms have opposing effects, with HIF-1α acting 
as a tumour suppressor, and HIF-2α acting as an oncogene (Schodel, Grampp et al. 2016). 
It has been suggested that there is a HIF switch during the development of RCC, where 
HIF-1α drives the acute response to hypoxia, and HIF-2α drives the chronic response to 
hypoxia (Koh and Powis 2012). Both HIF isoforms are activated under pseudohypoxic 
conditions due to the loss of VHL, but there is a gradual loss of HIF-1α expression, coupled 
with an increase in HIF-2α expression as tumour grade increases (Raval, Lau et al. 2005, 
Koh and Powis 2012). The oncogenic HIF-2α has been implicated in the deregulation of 
numerous target genes which affect proliferation including MYC, TGF-, VEGF, and p53 
(Gunaratnam, Morley et al. 2003, Schodel, Grampp et al. 2016). Studies have demonstrated 
the contrasting effects between the HIF isoforms, indicating that HIF-2α enhances tumour 
growth, whereas HIF-1α inhibits c-Myc activity and RCC proliferation (Raval, Lau et al. 
2005, Gordan, Lal et al. 2008). Given the fact that loss of HIF-1α was a notable hallmark 
of renal cell carcinoma, downregulation of HIF-1α is believed to be important in the 
pathogenesis of ccRCC. Indeed, Shen et al. (2011) found that the downregulation of HIF-
1α is associated with enhanced tumour growth in ccRCC, implicating it as a tumour 
suppressor (Shen, Beroukhim et al. 2011). 
Additionally, it has been shown that mutations in the VHL gene leads to upregulation of 
CXCR4 expression in RCC (Staller, Sulitkova et al. 2003). VHL normally acts as a tumour 
suppressor and negatively regulates CXCR4 expression via the degradation of HIF. 
However, when mutated, or under hypoxic conditions, HIF can induce CXCR4 expression. 
Overexpression of CXCR4 in RCC tumours is also associated with poor prognoses (Staller, 
Sulitkova et al. 2003, Zagzag, Krishnamachary et al. 2005). Another study demonstrated 
that the increased chemotactic response of CXCR4+ cancer cells towards CXCL12 
expressing targets is dependent on the stabilization of CXCR4 transcripts and the activation 
of HIF (Schioppa, Uranchimeg et al. 2003). Zagzag et. Al. found that the loss-of-function 
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of VHL was responsible for the upregulation of both CXCR4 and its ligand CXCL12 
(Zagzag, Krishnamachary et al. 2005).  
G proteins and GPCRs such as Gα12 and Gα13 are known to promote proliferation and 
metastasis in a variety of cancers (Dorsam and Gutkind 2007). In RCC, GTP-bound 
(active) Gα12 has been shown to bind to exchange factor for ARF6 (EFA6) and activate the 
ADP-ribosylation factor 6 (ARF6)-EFA6 pathway, which subsequently results in the 
process of EMT and the promotion of invasion and metastasis (Hashimoto, Mikami et al. 
2016). Gα12/13 have also been shown to regulate TGF-β1 (a known inducer of EMT) 
expression through a Rho/Rac-dependent pathway via activating protein-1 (AP-1) (Lee, 
Yang et al. 2009). It has been suggested that the upregulation of TGF-β1 results in 
increased matrix metallopeptidase (MMP) expression – proteases which play major roles 
in metastasis by degrading the ECM (Zhu, Liang et al. 2017). In support of this, a study 
found that increased expression of MMPs in tumours is dependent on the activation of Rho 
and Rac (Lozano, Betson et al. 2003). A study in breast cancer demonstrated that CXCR4-
mediated-chemotaxis and TEM of cancer cells is dependent on the coupling of Gα13 to 
CXCR4, which activates the downstream cascade of Rho and promotes chemotaxis 
towards CXCL12-expressing organs and subsequent extravasation (Yagi, Tan et al. 2011). 
Although the study was done in breast cancer, the CXCR4/CXCL12 axis has also been 
documented to play a pathological role in promoting invasion and metastasis in RCC 
(Staller, Sulitkova et al. 2003, Zagzag, Krishnamachary et al. 2005). Lastly, Gα13 has been 
shown to be responsible for proliferation, invasion, and EMT in RCC cells (Liu, Li et al. 
2017). Inhibition of Gα13 by the micro-RNA MiR-30b-5p effectively suppressed metastatic 
processes in RCC cell lines. Ultimately, there are many factors and molecules that 
contribute to the metastasis of RCC cells, and a greater knowledge of these molecular 
pathways would be beneficial in developing therapies to treating metastatic RCC. 
1.2.2 Current Therapies for RCC 
One of the major barriers to treating RCC currently is the ineffective detection of 
neoplasms at  early stages of the disease, as one third of patients present with metastasis at 
diagnosis (Custodio, Joaquim et al. 2012). In localized forms of the disease, where the 
neoplasms are relatively small and metastases are not present, surgery is the most effective 
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form of therapy (de Vivar Chevez, Finke et al. 2014). Radical or partial nephrectomy in 
these patients significantly improves their 5-year survival rate. In patients with metastatic 
forms however, surgery alone yields no improvement on survival, only palliation and 
symptom relief (de Vivar Chevez, Finke et al. 2014). In metastatic cases, the most effective 
form of treatment is surgery in conjunction with molecular-targeted therapy and 
immunotherapy (de Vivar Chevez, Finke et al. 2014).  
1.2.2.1 Molecular Targeted Therapy 
Molecular targeted therapies act on molecules in the RCC pathway which are specific to 
the disease, hence minimizing toxicities and adverse effects on other organs and tissues (de 
Vivar Chevez, Finke et al. 2014). Silencing of the VHL gene in RCC results in the 
overexpression of VEGF which contributes to the angiogenic nature of the disease (de 
Vivar Chevez, Finke et al. 2014). VEGF and molecules along the VEGF pathway have 
been the focus of molecular targeted therapy and the mainstay treatment for metastatic 
RCC (Su, Stamatakis et al. 2014). Sunitinib is part of a class of drugs known as receptor 
tyrosine kinase inhibitors (rTKI), which exert their effects through the inhibition of VEGF 
receptors (Su, Stamatakis et al. 2014). Sunitinib has become a first-line treatment in 
advanced RCC patients due to its relatively high response rate of 40% and an extended 
survival of 40 months (Finke, Rayman et al. 2013). Studies have also found that sunitinib 
can deplete peripheral myeloid-derived suppressor cells (MDSC) and improve T cell 
functions in hosts (Finke, Rayman et al. 2013, Su, Stamatakis et al. 2014). Resistance to 
rTKIs arises in patients over time and is currently an area of focus.  
The serine-threonine protein kinase mammalian target of rapamycin (mTOR) is a critical 
molecule in a multitude of biological pathways such as proliferation, metabolism, protein 
synthesis, and angiogenesis (de Vivar Chevez, Finke et al. 2014). Its expression is 
associated with worse outcomes in local and metastatic RCC patients (de Vivar Chevez, 
Finke et al. 2014). Two well-tested mTOR inhibitors: temsirolimus, and everolimus, are 
used as second-line treatment options in cases of disease progression after treatment with 
rTKIs and have demonstrated improvement in overall survival (Su, Stamatakis et al. 2014).  
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1.2.2.2 Immunotherapy 
Immunotherapy is a form of cancer treatment which harnesses the host’s own immune 
system to help eradicate the cancer. RCC is particularly amenable to immunotherapy owing 
to its immunogenic nature. While RCC elicits a strong immune response, RCC tumours 
evade immune destruction through a variety of mechanisms that ultimately render the 
activated  immune cells entering the tumour dysfunctional (Massari, Santoni et al. 2015). 
Over a decade ago, high-dose interleukin-2 (IL-2) and interferon-gamma (IFN-γ) were the 
cytokine treatments of choice for metastatic renal cancer (Massari, Santoni et al. 2015). IL-
2 promotes T cell proliferation and differentiation, whereas IFN-γ exerts anti-angiogenic 
effects, and promotes dendritic cell maturation (Raman and Vaena 2015). Although high-
dose IL-2 therapy appeared promising, only a small population of patients showed stable 
curative responses. Due to the significant treatment-related toxicities associated with high-
dose IL-2 therapy, only carefully selected patients were suitable for treatment (Raman and 
Vaena 2015). Clinical research has shifted towards alternative forms of immunotherapy 
with less adverse effects such as immune checkpoint inhibitors.  
Ground breaking research and identification of the checkpoint inhibitors cytotoxic T 
lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) have invited new 
possibilities for immunotherapy (Dong, Strome et al. 2002, Massari, Santoni et al. 2015). 
It is thought that CTLA-4 exerts its inhibitory effects during the priming and activation 
phase of T cells, whereas PD-1 exerts its inhibitory effects on effector T cells in the tumour 
microenvironment (TME) (Fife and Bluestone 2008, Massari, Santoni et al. 2015). PD-1 
has two ligands: PD-L1 and PD-L2. PD-L1 is expressed on many cells throughout the 
body, whereas PD-L2 is only expressed on macrophages and dendritic cells (Massari, 
Santoni et al. 2015). PD-1 is expressed on many immune cells such as T cells, B cells, and 
NKT cells to prevent auto-immunity in inflammatory sites; a mechanism which tumours 
exploit by expressing PD-L1 on their surface to inhibit T cell responses and avoid immune 
destruction (Massari, Santoni et al. 2015). Research has also shown that PD-L1 is 
aberrantly expressed on primary and metastatic RCC tissue, and that its expression is 
associated with worse patient outcomes (Thompson, Dong et al. 2007). Research into PD-
1/PD-L1 blockade therapy has shown promising results, with a well-studied anti-PD-1 
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antibody drug, nivolumab, producing a significant response rate of 27% in patients with 
RCC (Massari, Santoni et al. 2015). Nivolumab restores anti-tumour activity in patients 
and has been demonstrated to exert its activity within the TME (Philips and Atkins 2014). 
It has also been shown to produce relatively low levels of toxicity, accompanied with 
durable responses. 
1.2.3 Murine Model for Renal Cell Carcinoma 
The murine model for renal cell carcinoma is the most widely used model for studying the 
disease as it is the most analogous to the human form of the disease, thus treatments and 
responses can be effectively evaluated (Murphy and Hrushesky 1973). Two models are 
commonly used to study tumours in mice: the xenograft model and the syngraft model, 
which require immunodeficient and immunocompetent mice, respectively (White and 
Olsson 1980). The xenograft model requires either human RCC cell lines or a tumour graft 
from human samples, whereas in a syngraft model, the Renca cell line – derived from a 
spontaneously arising RCC cell line in BALB/c mice – is commonly used (Murphy and 
Hrushesky 1973). A disadvantage of cell lines is that they produce homogenous tumours, 
whereas human tumours are often heterogenous. An autochthonous murine model for 
ccRCC that recapitulates human ccRCC had long eluded scientists but recent 
groundbreaking work by Harlander et al. identified that mice harbouring combined Vhl, 
Trp53 and Rb1 mutations caused spontaneous ccRCC (Harlander, Schonenberger et al. 
2017). The study found that the mice developed genetically distinct ccRCC tumours and 
were molecularly similar to the human disease, thus providing a useful tool to investigate 
pre-clinical therapeutic studies. 
1.2.3.1 Xenograft Model 
In the xenograft model, fresh human tumours or established human cell lines can be 
successfully xenografted into immunodeficient mice and can propagate into solid tumours 
(White and Olsson 1980). The three most commonly used immunodeficient mouse strains 
are: nude athymic mice, which lack T cells; severe combined immunodeficient (SCID) 
mice, which lack B and T cells; and non-obese diabetic (NOD)/SCID mice, which lacks 
both B and T cells, and has decreased functional macrophages, granulocytes, and NK cells 
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(White and Olsson 1980). Human RCC cell lines are widely used in murine models to 
accurately study and characterize tumour development and progression, and has been 
important to understanding the cell biology of renal cancer (Morton and Houghton 2007). 
Currently, multiple human RCC cell lines are available: ACHN, A-498, 786-O, 769-P, 
Caki-1, and Caki-2 (Morton and Houghton 2007, Brodaczewska, Szczylik et al. 2016). Of 
the aforementioned cell lines, only A-498, 786-O, and 769-P have a VHL mutation, making 
them ideal choices to study ccRCC specifically. 786-O was one of the earliest established 
RCC cell lines and is most commonly used, as it also expresses elevated VEGF levels 
(Shinojima, Oya et al. 2007), a characteristic of ccRCC. The 769-P cell line also expresses 
high levels of VEGF, however, its use in xenograft models has been constrained as studies 
found it lacked tumourigenicity when injected subcutaneously or intravenously into mouse 
models (Kozlowski, Fidler et al. 1984, Miyake, Goodison et al. 2013). A major limitation 
of the xenograft model is the fact that the mice are immunodeficient, thus making it 
impossible to study the immune component of RCC and its interactions with the established 
tumours. 
1.2.3.2 Syngraft Model 
The syngraft model involves the establishment of immunologically compatible tumours in 
immunocompetent mice and is advantageous as it makes studying the interaction between 
immune cells and the tumours, as well as tumour progression and metastasis possible. The 
use of the Renca cell line in the RCC mouse model has been studied extensively since the 
70s (Murphy and Hrushesky 1973). The growth and progression of the solid tumours 
follow a predictable timeline, as does the spread of secondary tumours. The growth and 
dissemination of the RCC tumours in this model are also consistent and reproducible, and 
strongly recapitulate the disease in humans, making the Renca cell line a popular model to 
use (Murphy and Hrushesky 1973). Furthermore, the Renca cell line reflects the 
immunogenic nature of human RCC, as repeated tumour challenges in mice resulted in 
decreased incidence.  
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1.2.4 Murine Model for Metastasis 
To study metastasis in mice, three tumour transplant models are commonly used: the 
experimental metastasis model, the spontaneous metastasis model, and the genetically 
engineered mouse model (Gomez-Cuadrado, Tracey et al. 2017). For the purposes of this 
thesis, only the former two models will be discussed.   
1.2.4.1 Experimental Metastasis Model 
Experimental metastasis models allow for the rapid and reproducible development of 
metastases in specific organs (Gomez-Cuadrado, Tracey et al. 2017). Depending on the site 
of study, cancer cells can be injected intravascularly, and the route of injection determines 
the site of colonization (Khanna and Hunter 2005). For example; intravenous injections in 
the lateral tail vein result in lung metastases; intracardiac injections result in brain and bone 
metastases; and intraperitoneal injections result in ovarian metastases (Gomez-Cuadrado, 
Tracey et al. 2017). A major limitation of the experimental model is that they only reflect 
the late stages of the metastatic process, particularly the arrest and extravasation steps, and 
subsequent development of tumours in ectopic sites. 
1.2.4.2 Spontaneous Metastasis Model 
Spontaneous metastasis models on the other hand, allow for the metastatic disease to be 
studied in a manner that mimics the disease progression in humans. The cancer cells are 
transplanted orthotopically, and the entire metastatic cascade can be monitored as the 
primary tumour grows and disseminates naturally to the secondary site (Gomez-Cuadrado, 
Tracey et al. 2017). Orthotopic models can therefore recapitulate the disease in humans 
better as it allows cancers to interact with the tissue of origin and elicit natural responses, 
which also include the earlier stages of metastasis such as invasion and intravasation 
(Francia, Cruz-Munoz et al. 2011). Spontaneous models however, require greater expertise 
to implant the cancer cells properly in the orthotopic site (Gomez-Cuadrado, Tracey et al. 
2017).  
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1.3 Kidney Injury Molecule 
Kidney injury molecule-1 (KIM-1), also known as T cell immunoglobulin mucin domain 
1 (TIM-1) and hepatitis A virus cellular receptor 1 (HAVCR1), belongs to the family of 
TIM proteins, which are type-1 cell surface glycoproteins involved in the regulation of T 
cell activation and tolerance (Han, Alinani et al. 2005), and is a highly upregulated 
marker in the proximal tubule after renal injury (Brodaczewska, Szczylik et al. 2016). It 
has a heavily glycosylated ectodomain that is cleaved and released into the lumen, and 
can be detected in the urine and blood of humans, mice, and rats following kidney injury 
(Ichimura, Bonventre et al. 1998, Sabbisetti, Waikar et al. 2014). 
1.3.1 Function 
Phosphatidylserine is expressed on the surface of apoptotic and necrotic cells (Fadok, 
Savill et al. 1992, Zargarian, Shlomovitz et al. 2017). KIM-1 is a phosphatidylserine 
receptor that transforms proximal tubular epithelial cells (PTEC) into semi-professional 
phagocytic cells that can recognize and enhance the clearance of apoptotic cells and 
necrotic cells, thus making it an important molecule in the regulation of the immune 
response after kidney injury (Ichimura, Asseldonk et al. 2008, Arai, Kitada et al. 2016). 
The rapid clearance of dead cells prevents excessive inflammation and auto-immune 
responses against intracellular antigens released from dying cells (Kobayashi, Karisola et 
al. 2007). Normally, KIM-1 preferentially binds and internalizes apoptotic cells over 
necrotic cells, but in the presence of the protein apoptosis inhibitor of macrophages (AIM), 
KIM-1-mediated clearance of necrotic cells is significantly increased (Molitoris 2014, 
Arai, Kitada et al. 2016). It has been shown that following kidney injury, AIM expression 
increases in the tubular lumen, where it binds necrotic debris and mediates phagocytosis 
by PTECs expressing KIM-1 (Arai, Kitada et al. 2016).  
It has been suggested that KIM-1 can elicit opposite effects in the kidney; KIM-1 is 
protective early in acute kidney injury (AKI) (Yang, Brooks et al. 2015), but sustained 
expression leads to kidney fibrosis, progressive interstitial kidney inflammation, and 
chronic kidney disease (CKD), thus providing a potential link between AKI and CKD 
(Humphreys, Xu et al. 2013). 
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1.3.2 Role of KIM-1 in RCC 
Following acute kidney injury, PTECs (including those expressing KIM-1) undergo de-
differentiation, proliferation, and re-differentiation in order to repair the tubular epithelium 
(Humphreys, Xu et al. 2013). However, the de-differentiation of PTECs is heterogenous in 
nature, and only some of the regenerating cells express KIM-1 (Kusaba, Lalli et al. 2014). 
Similar to injured PTECs, RCC cells also exist in a state of de-differentiation (Shimazui, 
Oosterwijk-Wakka et al. 2000). Not surprisingly, KIM-1 is expressed in >90% of human 
RCC tissue samples (Bonventre 2014, Zhang, Mashni et al. 2014). 
KIM-1 is highly expressed in the two most prevalent forms of RCC: clear cell RCC, and 
papillary RCC, and can serve as a non-invasive biomarker for the early diagnosis of the 
disease through the detection of the shed ectodomain in the urine of patients (Han, Alinani 
et al. 2005, Zhang, Mashni et al. 2014). Studies have shown that significantly greater levels 
of KIM-1 were detected in the urine samples of ccRCC patients compared with patients 
with prostate carcinoma or control subjects (Bonventre 2014, Zhang, Mashni et al. 2014). 
In contrast, KIM-1 is absent in normal kidney tissue, and it has been demonstrated that 
patients who tested positive for KIM-1 expression pre-nephrectomy showed either 
complete disappearance or marked reduction in KIM-1 expression post-nephrectomy (Han, 
Alinani et al. 2005, Bonventre 2014). It has recently been shown that plasma KIM-1 
concentrations can serve as a reliable biomarker for the prediction of RCC onset up to 5 
years before diagnosis (Scelo, Muller et al. 2018). Combined, these studies indicate that 
KIM-1 is a sensitive and specific biomarker for the early detection of RCC.   
One study has shown that overexpression of KIM-1 promotes tumour growth in human 
769-P cells, whereas silencing of the gene led to a reduction in cancer cell proliferation 
(Cuadros, Trilla et al. 2014). The same study found that KIM-1 activates the STAT-3/IL-
6/HIF-1α axis in ccRCC, which indicates KIM-1s involvement in the pathway for tumour 
growth and angiogenesis. KIM-1 expression on RCC cells is associated with increased 
levels of transforming growth factor beta (TGF-β), which has been shown to promote 
metastatic invasion (Bostrom, Lindgren et al. 2013, Sabbiseti 2014). In contrast, a study 
previously published by our lab demonstrated that KIM-1 expression on TECs inhibits 
Gα12, which consequently results in the inhibition of downstream RhoA – a small GTPase 
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involved in invasion and metastasis (Ismail, Zhang et al. 2016). We however have not 
examined the role of KIM-1 and G12 in RCC cells. Therefore, the precise role that KIM-
1 plays in RCC remains poorly understood.  
1.4 Rationale, Objective, and Hypothesis 
1.4.1 Rationale 
RCC is the most common form of kidney cancer, and makes up over 90% of all cases (De, 
Otterstatter et al. 2014). Patients with stage IV metastatic RCC have a frighteningly low 5-
year survival rate of only 8%, of whom comprise of over 30% of patients at the time of 
diagnosis (Canadian Cancer Society 2015). Current available therapies fall short due to the 
development of resistances and toxicities, compounded with suboptimal response rates in 
clinical trials (Massari, Santoni et al. 2015, Raman and Vaena 2015). Targeted therapies 
such as mTOR inhibitors, and VEGF inhibitors have been limited by resistance and toxicity 
(Su, Stamatakis et al. 2014), and immunotherapies such as PD-1/PD-L1 inhibitors have 
demonstrated limited response rates in clinical trials (Massari, Santoni et al. 2015). Surgery 
is often the most effective form of treatment in patients with non-metastatic RCC, but only 
offers palliation and symptom relief in patients with the metastatic form of the disease (de 
Vivar Chevez, Finke et al. 2014). There is hence an urgent need for novel therapeutic 
targets for the treatment of metastatic RCC.  
In RCC, studies have found that KIM-1 is overexpressed in over 90% of RCC tumours, 
which includes the 2 most prevalent and aggressive forms of the disease: clear cell and 
papillary (Bonventre 2014, Zhang, Mashni et al. 2014). This overexpression is important 
since it is absent in healthy kidneys, and either absent or markedly reduced in patients that 
have undergone nephrectomy. The biological significance of this overexpression is still 
unclear; it is unknown whether KIM-1 overexpression promotes the disease, or if KIM-1 
is overexpressed because of the disease.  
The Cancer Genome Atlas (TCGA) is a publicly available cancer genomics program that 
has characterized the molecular profiles of over 20,000 primary cancers and profiled 33 
types of cancers (National Cancer Institute 2006). We mined TCGA database in hopes of 
understanding how KIM-1 expression correlates with clinical outcome in patients. From 
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our unpublished data, we found that the high KIM-1 expressing patients had surprisingly 
greater overall survival compared with low KIM-1 expressing patients (Appendix A 1). 
Despite KIM-1 being absent in healthy kidneys, and it being overexpressed in the majority 
of RCC tumours, there appears to be an apparent protective effect in human patients.  
There remains a vacuum in understanding on the role that KIM-1 plays in the metastasis 
of RCC in humans. KIM-1 appears to be a promising candidate to study and may lead to 
the development of novel therapeutic targets for the treatment of metastatic RCC. Given 
that metastasis is the most common cause of death in patients with RCC, and that KIM-1 
expression is predictive of overall survival, KIM-1 may play a role in regulating metastasis 
in RCC. Determining whether KIM-1 plays a role in the development of metastatic RCC 
and elucidating the mechanisms behind its effects in RCC would be beneficial to 
understanding metastasis in the disease.   
1.4.2 Objective and Hypothesis 
The objective of this study was to determine the role that KIM-1 plays in the metastatic 
cascade of RCC and to elucidate the mechanism behind the action of KIM-1 and its 
downstream effectors. This study could ultimately help identify KIM-1 as a novel 
therapeutic target for the treatment of metastatic RCC.  
We hypothesized that KIM-1 inhibits the metastatic potential of RCC cells. The specific 
aims of the work outlined in this thesis were; 1) To determine whether KIM-1 inhibits 
metastatic capabilities in vitro; 2) To determine whether KIM-1 inhibits invasion and 
metastasis in vivo; 3) To determine whether KIM-1-mediated inhibition of metastasis is 
dependent on adaptive immunity, and; 4) Elucidate genes that are differentially expressed 
between KIM-1+ and KIM-1neg cells. We predicted that; KIM-1 expression on RCC cells 
inhibits cancer cell invasion and metastasis both in vitro and in vivo; KIM-1-mediated 
inhibition of invasion and metastasis in vivo is independent of any contribution from the 
adaptive immune system, and; KIM-1 expression inhibits downstream effectors involved 
with invasion and metastasis.  
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Chapter 2  
2 Materials and Methods 
2.1 Generation of Stable Cell Lines 
2.1.1 Plasmid Preparation and Transfection 
Dr. Lawrence Kane (University of Pittsburgh, Pittsburgh, PA) generously provided the 
pCDEF3-mTim-1 (mKim-1) plasmid (Addgene plasmids # 49206; Cambridge, MA) and 
the parental pCDEF3 plasmid. DH5α competent cells transformed with either the pCDEF3-
mKim-1 plasmid or pCDEF3 vector alone were grown overnight in LB media (1% w/v 
tryptone, 0.5% w/v yeast extract, 1% w/v NaCl) with 100 mg/ml ampicillin at 37° C with 
shaking. Plasmids were isolated using Geneaid midi plasmid kit (Geneaid Biotech Ltd., 
New Taipei City, Taiwan) following the manufacturer’s protocol. Renca cells were plated 
in 6-well plates in complete medium and incubated until cells reached approximately 70% 
confluency. Renca cells stably expressing Kim-1 (Renca-pCDEF3-Kim-1) or pCDEF3 
(Renca-pCDEF3) were generated by transfecting them with 2.5 μg of either pCDEF3-Kim-
1 or pCDEF3 vector using 6 μl Lipofectamine® 2000 (ThermoFisher Scientific). After 24 
h, the Renca cells were moved to a 15-cm plate and subjected to G418 selection (400 μg/ml) 
48-h post-transfection. Renca cells were cultured continuously in the presence of G418 
until non-transfected cells were completely killed. G418-resistant colonies were picked by 
aspirating medium, washing cells with 1x phosphate-buffered saline (PBS; 137 mM NaCl, 
2.7 mM KCl, 4.3 mM Na2HOP4, 1.47 mM KH2PO4, pH 7.4) solution, and incubating 
cells with pre-cut pieces of filter paper soaked in 0.25% trypsin-EDTA (Invitrogen) for 5 
minutes in a 37°C, 5% (v/v) CO2 incubator. Filter paper with attached cells were picked 
and grown in 24-well plates in full medium containing 400 μg/ml G418 until cells reached 
confluency. Individual colonies were then expanded, and Kim-1 expression was confirmed 
using western blot.  
2.1.2 Stable Expression of Kim-1 Using Lentiviral Particles 
Lentivirus ORF particles containing a vector with the murine Kim-1 gene, Havcr1 and a 
puromycin resistance gene (MR203831L3V; Origene, Rockville, MD) were used to 
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transduce Renca cells (herein referred to as Kim-1+ Renca). A control lentivirus ORF 
particle containing the same vector but lacking the Kim-1 transcript (PS100092V; Origene) 
was used as a control (Kim-1neg Renca). The optimal concentration of lentiviral particles 
to use was determined based on testing various multiplicities of infection (MOIs), which 
is the number of transducing lentiviral particles per cell. To calculate the total transducing 
units (TU) needed; the total number of cells per well is multiplied by the desired MOI. 
Then, the total TU needed is divided by the titer of the virus purchased in TU/ml to give 
the total mL of lentiviral particles to be added to each well. Renca cells were seeded on a 
24-well plate in full medium and incubated for 24 h when 75% confluency was reached. 
The medium was aspirated and replaced with full medium containing 8 μg/mL of polybrene 
(Santa Cruz Biotechnology) and the appropriate number of lentiviral particles (either 
control particles or particles containing the Kim-1 transcript). After 24 h, the medium was 
aspirated and replaced with full medium. 72 h post-transduction, stable cell lines were 
selected for using medium supplemented with puromycin. Medium was aspirated and 
replaced with full medium containing 2 μg/ml of puromycin every 2–3 days for two weeks. 
After two weeks, cells transduced with Kim-1 ORF lentiviral particles were screened for 
Kim-1 expression via western blot and PCR. 
2.1.3 shRNA Knock-down of Endogenous KIM-1 Using Lentiviral 
Particles 
Lentiviral particles containing three human KIM-1-specific constructs encoding shRNA 
(sc-61691; Santa Cruz) were used to knockdown KIM-1 in the 769-P and 786-O cell line 
(herein referred to as 769-P-/786-O-shKIM-1). Control transduction was done using 
control scrambled shRNA lentiviral particles (769-P-/786-O-shcontrol) (sc-108080; Santa 
Cruz). 769-P/786-O cells were plated on a 12-well plate in full medium and incubated for 
24 h until 75% confluency was reached. The medium was aspirated and replaced with 1 
mL total volume of full medium containing 8 μg/mL of polybrene (Santa Cruz 
Biotechnology) and 25 μL of lentiviral particles (either shKIM-1 or shcontrol lentiviral 
particles). After 24 h, the medium containing polybrene and lentiviral particles was 
aspirated and replaced with complete medium. 72-h post-transduction, stable cell lines 
expressing the respective shRNA were isolated via selection with puromycin. Medium was 
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aspirated and replaced with full medium containing 4 μg/ml of puromycin every 2–3 days 
for two weeks. After two weeks, knockdown of KIM-1 in 769-P and 786-O cells was 
confirmed via western blot and PCR. 
2.2 Western Blot 
Confluent monolayers of the respective cells (Renca, 769-P and 786-O) were lysed with 
ice cold 4% sodium dodecyl sulfate (SDS) and centrifuged at 15,000 x g for 10 minutes. 
The supernatants were collected for western blot analysis. Protein concentrations were 
determined using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) and samples 
were prepared such that they contained 50 μg of total protein. Proteins were separated by 
SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (EMD 
Millipore, Billerica, MA). Membranes were blocked with blocking buffer (Tris-buffered 
saline, 0.1 % Tween-20 (ThermoFisher Scientific), and 5% non-fat dried milk (Carnation)) 
for 1 h. Membranes were then incubated overnight at 4°C with primary antibodies: 
extracellular domain of human KIM-1 (AKG; Dr. Bonventre, Harvard Medical School, 
Cambridge, MA), extracellular domain of mouse Kim-1 (AF1817; R&D systems, 
Minneapolis, MN), or GAPDH (6C5; Santa Cruz Biotechnology). Membranes were 
washed and incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibody (dilution 1:30000; Jackson ImmunoResearch Laboratories, West Grove, PA) for 
1 h at room temperature in blocking buffer. Proteins were visualized using Luminata Forte 
Western HRP Substrate (EMD Millipore) and developed using the FluorChem M system 
(ProteinSimple, San Jose, CA). 
2.3 RNA Extraction and cDNA Synthesis 
Cell and tissue samples were collected in TriPure isolation reagent (Roche Diagnostic, 
Basel, Switzerland). 200 μL of chloroform per 1 mL of TriPure reagent used was added to 
samples and then mixed vigorously. The samples were incubated for 10 minutes at room 
temperature and then centrifuged at 12,000 x g for 20 minutes at 4°C. The aqueous layer 
was carefully recovered in a fresh tube and an equal volume of isopropanol was added to 
the aqueous layer for precipitation. The mixture was vortexed briefly, incubated at room 
temperature for 10 minutes, and then centrifuged at 12,000 × g for 10 minutes at 4°C. The 
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supernatant was removed from the tube and the pellet was washed with 70% ethanol, and 
subjected to centrifugation at 7,500 x g for 5 minutes at 4°C.  After removal of the 
supernatant, the pellet was resuspended in DEPC-treated water and quantified with 
spectrophotometry (260 and 280 nm; MultiskanTM GO Microplate Spectrophotometer; 
ThermoFisher Scientific). 1 μg of total RNA and 4 μL of qSCRIPT cDNA SuperMix 
(Quanta Biosciences, Gaithersburg, MD) were used to generate cDNA using the 
MyCyclerTM thermal cycler (Bio-Rad, Hercules, CA). 
2.3.1 Real Time-PCR (RT-PCR) 
RT-PCR was performed using the StepOnePlus Real-Time PCR System (Applied 
Biosystems, Waltham, MA) and SYBR Green detection (ThermoFisher Scientific). The 
reaction mixture had a total reaction volume of 20 μL, which consisted of 10 μL of SYBR 
Green Master Mix, 0.2 μL of each 10 μM forward and reverse primer for the gene of 
interest, 4.6 μL of DEPC treated water, and 5 μL of cDNA diluted in DEPC-treated water 
at a ratio of 1:10. Primers for KIM-1 and GAPDH are shown in Table 1 (Integrated DNA 
Technologies, Coralville, IA). Normalization of the target gene was performed to GAPDH 
to compensate for inter-PCR variations. Relative gene expression was calculated using the 
2-ΔΔCt method. 
2.3.2 Standard PCR 
The reaction mixture had a total volume of 25 μL, which consisted of cDNA, DEPC treated 
water, 200 μM of forward and reverse primer for the gene of interest, 2 U/rxn of Taq DNA 
polymerase (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 0.2 mM of dNTP mix (Clontech 
Laboratories, Mountain View, CA), and 1x PCR Reaction Buffer (Invitrogen). Primers for 
KIM-1 and GAPDH are shown in Table 1 (Integrated DNA Technologies). Amplicons 
were resolved using a 1% agarose gel via gel electrophoresis in 1x TBE buffer 
(Tris/borate/EDTA; 0.09 M Tris (hydroxymethyl) Aminomethane, 0.09 M Boric Acid, 0.1 
mM EDTA). Amplicons were visualized with ethidium bromide and UV light using the 
FluorChem M system (ProteinSimple). Target genes were normalized to GAPDH. 
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2.1 Cell Culture 
The murine RCC line, Renca, was purchased from ATCC (CRL-2947). Cells were 
maintained according to ATCC recommendations. Cells were cultured in RPMI-1640 
medium, supplemented with L-glutamine and 25 mM HEPES (Lonza, Walkersville, MD), 
10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA), 2 mM L-glutamine 
(ThermoFisher Scientific, Waltham, MA), 1 mM sodium pyruvate (ThermoFisher 
Scientific), 0.1 mM non-essential amino acids (ThermoFisher Scientific), and 5% 
penicillin streptomycin (PS; Invitrogen). Stable Renca cell lines were maintained with 2 
mM puromycin dihydrochloride (Sigma-Aldrich, St. Louis, MO). The human RCC cell 
lines, 786-O and 769-P, were purchased from ATCC (CRL-1932). Cells were cultured in 
DMEM medium, supplemented with L-glutamine, sodium pyruvate, and phenol red 
(Wisent Bioproducts, Saint-Jean Baptiste, QC), 10% FBS, and 5% PS. Stable 786-O cell 
lines were maintained with geneticin sulfate (G418; Santa Cruz Biotechnology, Santa Cruz, 
CA). All cells were maintained in a 37⁰ C, 5% (v/v) CO2 incubator.  
2.2 Migration and Invasion Assay 
Cell migration and invasion were used as surrogates for metastatic potential of RCC cells 
in vitro. Transwell culture plates with 8.0-μm-pore-size polycarbonate membrane filter 
inserts with 6.5 mm diameter (Corning, NY) were used to perform migration and invasion 
assays. Plate wells were filled with 800 µL of serum-free media (SFM) or complete media 
with 10% FBS (Renca in RPMI; 786-O in DMEM). Renca cells were cultured to a 
confluency of ~80% and resuspended in SFM at a concentration of 2x105 cells/mL. 786-O 
cells were cultured to 100% confluency, starved for 24h prior to collection, and 
resuspended in SFM at a concentration of 1x105 cells/mL. 200 µL of cells were seeded in 
the Transwell insert and plates were incubated for 24 h in a 37⁰ C, 5% (v/v) CO2 incubator. 
For invasion assays, Transwell inserts were coated with 200 µL of Matrigel (1:100 dilution 
in SFM; BD Biosciences, NJ) 24 h prior to seeding of cells. After incubation, media was 
aspirated from the inserts and wells, and lightly blotted dry using cotton swabs. 
Subsequently, 1 mL of cold methanol was added to each well, and inserts were replaced 
and incubated at RT for 5 minutes to fix the cells. Methanol was aspirated, and 1 mL of 
eosin dye (Sigma-Aldrich) was added to each well and incubated at RT for 5 minutes. This 
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process was repeated using a secondary toluidine blue dye (Sigma-Aldrich). Wells were 
then washed twice at RT with 2 mL of distilled water for 5 minutes each. Inserts were then 
removed and placed upside down to dry on benchtop for 30 minutes. Using a scalpel blade, 
insert membranes were carefully cut out, fixed on a glass slide and allowed to dry overnight 
at RT. Light microscopy was used to quantify the migrated and invaded cells. All assays 
were performed in triplicate.  
2.3 Extravasation Efficiency Assay in the CAM of Chick 
Embryos 
Methods and protocols for CAM extravasation model was conducted by Marie Sarabusky 
as previously described in the laboratory of Dr. Hon Leong (then) at the Lawson Health 
Research Institute (Kim, Williams et al. 2016). Renca and 769-P cells were plated on cell 
culture flasks and grown until 80% confluency was obtained. Medium was aspirated, cells 
were washed with 1x PBS, and then cells were incubated for 5 minutes with 0.25% trypsin-
EDTA in a 37°C, 5% (v/v) CO2 incubator. Cells were centrifuged for 5 minutes at 500 x 
g, the supernatant was aspirated, and cells were resuspended in 1 mL of 1x PBS. Cells were 
fluorescently labeled using 1 μL of CellTracker dye (ThermoFisher Scientific) and 
incubated on ice for 5 minutes. Cells were centrifuged for 5 minutes at 500 x g and the 
supernatant was aspirated. A day 13 embryo was placed under a dissecting scope with 
white light illumination in order to visualize the veins in the CAM. The cell suspension 
was drawn up into a microinjector and 1x105 KIM-1+ or KIM-1neg cells were injected into 
the vein of the CAM. Following the injection, two filter square windows were placed on 
the surface of the embryo at sites away from the injection site. A wide-field fluorescent 
microscope at 10x objective was used to count and record all the cells within each square 
window immediately after injection. All cells at this time point (T = 0 h) are intravascular. 
24 h later, the fluorescent microscope was used again to count and record the number of 
intravascular and extravascular cells (T = 24 h). The extravasation efficiency was 
determined by dividing the number of extravasated cells at T = 24 h by the number of 
intravascular cells at T = 0 h in each of the square windows (Kim, Williams et al. 2016). 
The mean extravasation efficiency for all foil windows on each embryo was then 
determined. To obtain intravital images of intravascular and extravasated cells, the CAM 
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was additionally injected with lectin-DyLight 649 (Vector Laboratories, Burlington, ON) 
and Dextran-Alexa 555 (ThermoFisher Scientific) and imaged using a confocal microscope 
(Olympus, Tokyo, Japan) with the 60x objective at T = 0 h and T = 24 h. 
2.4 Mice 
Female wild-type (WT) BALB/c mice were purchased from Charles River Laboratory 
(Wilmington, MA) and maintained in the pathogen-free animal facility at Western 
University. Mice were kept in standard shoebox cages with access to pellet food and bottled 
tap water in rooms maintained at constant temperatures (22⁰ C) with 12-h light/12-h dark 
cycles. Immune-deficient C129-Rag (Rag1-/-) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) and maintained in the pathogen-free barrier facility at 
Western University. Mice were kept in pathogen-filtered shoebox cages with access to 
pellet food and water through a filtered nozzle, and maintained in similar room conditions. 
Experimental mice were monitored every 2 days for physiological and behaviour changes. 
All mice were euthanized using CO2 chambers, and post-mortem procedures were 
conducted as described. All animal protocols (2010-230, later renewed 2018-147) and 
experiments were approved by Western University’s Animal Use Subcommittee in 
compliance with the guidelines set by the Canadian Council of Animal Care. 
2.5 Experimental Metastasis Model 
2.5.1 Intravenous Injection of RCC cells 
To study experimental metastasis of RCC cells into the lungs, 6-10-week-old female WT 
BALB/c mice were injected with Renca cells via lateral tail vein. Renca cells were cultured 
in cell culture flasks up to a confluency of 80%. Media was aspirated, and cells were 
washed with 5 mL of cold 1x PBS, and then incubated with 10 mL of cold 1x PBS at room 
temperature (RT) for 10 minutes. PBS was aspirated and replaced with 3 mL of 0.25% 
trypsin-EDTA (Wisent Bioproducts) for 5 minutes in a 37⁰ C, 5% (v/v) CO2 incubator. 
Cells were then flushed with 6 mL of complete RPMI-1640 media to dislodge adherent 
cells, which were then collected and centrifuged at 500 x g for 5 minutes, and the 
supernatant was subsequently aspirated. Cells were counted using trypan blue and a 
hemocytometer, and viable cells were then resuspended at a concentration of 2.5x106 
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cells/mL in sterile 1x PBS. Mice were restrained using a cylindrical mouse restrainer 
(Stoelting, Wood Dale, IL) and injected with 200 µL (5 x 105 cells) of Renca cells via the 
lateral tail vein, using a ½ inch 28-gauge insulin syringe (Becton Dickinson, Franklin 
Lakes, NJ). Mice were monitored after 24 h, and then every 2 days until day 17, at which 
point, they were euthanized using a CO2 chamber. To study whether KIM-1-mediated 
inhibition of metastasis is dependent on adaptive immunity, Renca or 786-O cells were 
instead injected into the tail veins of immune-deficient BALB/c (Rag1-/-) mice in the same 
manner as described above. 
2.5.2 Staining of Lungs and Visualization of Metastatic Nodules 
We used a modified version of the protocol described by Zimmerman et al. (Zimmerman, 
Hu et al. 2010) to stain the lungs of mice injected either intravenously or orthotopically 
with RCC cells and for visualization of metastatic nodules. Euthanized mice were pinned 
down on their dorsal side, and their chest cavity was opened up along the sternum using 
scissors to expose the lungs and trachea. The trachea was clamped down at the highest 
possible point with tweezers, and 2 mL of 15% India black ink (diluted in distilled water) 
was slowly injected into the trachea below the clamp, expanding the lungs and turning 
them black. Lungs were excised, detached from the heart and thymus, and placed in a 
beaker of distilled water for 5 minutes to wash off excess ink. The lungs were then 
transferred to a 15 mL Falcon tube (ThermoFisher Scientific) containing 5 mL of Fekete’s 
solution (Appendix A 2) to expose the metastatic tumour tissue as white nodules. Lungs 
were incubated overnight at 4⁰ C before being washed with 1x PBS and metastases counted 
under a low power light microscope.   
2.6 Spontaneous Metastasis Model 
To study the spontaneous metastasis of RCC cells to the lungs, Renca cells were 
orthotopically injected into kidney capsules of 10-14-week-old female WT BALB/c mice. 
Mice were first anesthetized with Ketamine/Xylazine (100 mg/kg, 16 mg/kg), and given 
slow-release buprenorphine (1 mg/kg) for pain control. The drugs were injected 
subcutaneously according to institutional guidelines. Injection site (left flank) was shaved 
and prepared with 5% povidone-iodine antiseptic. An incision (~1.5-2 cm) was carefully 
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made using sterile scalpel and scissors to not penetrate the peritoneum. The dermis layer 
and peritoneum were then carefully separated. The kidney was identified underneath the 
spleen and held in place using forceps. Carefully, 30 µL of cell suspension (2 x 105 cells 
in a 1:1 ratio with Matrigel) was injected into the subcapsular space of the kidney and held 
in place for a minute while a heat lamp was placed overhead to solidify the Matrigel. The 
incision was closed, and the animal was returned to its cage and monitored until it 
recovered to parameters set by institutional guidelines. Once the injections were completed, 
the mice were monitored after 24, 48, and 72 h, and then every 2 days after until day 17. 
Mice were then sacrificed, and lungs were stained and collected as described previously.  
2.7 RNA Sequencing 
RNA sequencing was performed by London Genomics Centre under the guidance of Dr. 
Rob Hegele at the Robarts Research Institute (Western University). RNA extraction and 
cDNA library synthesis were performed as described above with Kim-1+ and Kim-1neg 
Renca cells. Adapter sequences specific to the Illumina sequencing platform was used. 
Libraries were sequenced using the Illumina NextSeq 500 sequencer (Illumina Inc., San 
Diego, CA). A bioinformatic pipeline was built using the Partek Flow software (Partek 
Inc., St. Louis, MO) to compare differences in gene expression between Kim-1+ and Kim-
1neg Renca cells. A heat map was generated by changing parameters to only include genes 
with significant differences with p < 0.05 and exclude fold-changes between -1.5 and 1.5 
(Figure 9). Gene pathway and gene set enrichment were performed to determine biological 
pathways and specific genes relevant to invasion and metastasis. The same stringency 
values used to generate the heat map were applied. The pathways and genes are displayed 
in Table 2 and 3.   
2.8 Statistical Analysis 
Differences in means between KIM-1+ and KIM-1neg groups for all results were analyzed 
using unpaired two-tailed t-tests. Statistical significance was defined as: *, p < 0.05; **, p 
< 0.01; ***, p < 0.001. Data was represented as mean ± SEM. Statistical analyses were 
performed using the GraphPad Prism, version 8 software. 
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Chapter 3  
3 Results 
3.1 Renca cells expressing Kim-1 exhibited decreased 
metastatic potential in vitro 
To understand the metastatic potential of Renca cells in vitro, Transwell migration and 
invasion assays were performed (Figure 3). Renca cells were seeded in the Transwell 
inserts, and SFM or complete media (RPMI with 10% FBS) was loaded (underneath) into 
the plate wells. For invasion assays, the Transwell insert membranes were coated with 
Matrigel prior to cell seeding. Kim-1+ Renca cells showed significantly reduced migratory 
capability compared with Kim-1neg Renca cells in both the SFM group (22.67 vs. 40.33), 
and the 10% group (51 vs. 76.67), respectively (n = 3; SFM, p = 0.0049; 10%, p = 0.0307) 
(Figure 3A). Kim-1+ Renca cells also exhibited significantly fewer invading cells 
compared with Kim-1neg Renca cells, in the SFM group (35.33 vs 50.33), and in the 10% 
group (34 vs. 49.33), respectively (n = 3; SFM, p = 0.0006; 10%, p = 0.0005) (Figure 3B). 
Together, these data demonstrate that Kim-1 expression inhibits the migration and invasion 
of Renca cells in vitro.  
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Figure 3. Transwell migration and invasion assay of Kim-1+ and Kim-1neg Renca cells. 
(A) Migration assay of Kim-1+ and Kim-1neg Renca cells (n=3) (B) Invasion assay of Kim-
1+ and Kim-1neg Renca cells (n=3). (C) Images of migration assay Transwell insert 
membranes (10X) (D) Images of invasion assay Transwell insert membranes (10X). 2 x 
105 Renca cells were seeded in serum-free RPMI media in Transwell inserts on top of wells 
filled with serum-free or complete RPMI media supplemented with 10% FBS. Plates were 
incubated at 37⁰ C for 24h. Transwell insert membranes for invasion assay were coated 
with Matrigel 12h prior to seeding. Data is represented as mean number of cells ± SEM 
(A; SFM, p = 0.0049; 10%, p = 0.0307. B; SFM, p = 0.0019; 10%, p = 0.0028, Unpaired 
two-tailed t-test). SFM, serum-free media; 10%, complete RPMI media supplemented with 
10% FBS. 
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3.2 KIM-1 expression on 786-O cells inhibits invasion in 
vitro 
To understand the metastatic potential of human RCC (786-O) cells in vitro, Transwell 
migration and invasion assays were performed (Figure 4). 786-O cells were seeded in the 
Transwell insert, and SFM or complete media (DMEM with 10% FBS) was loaded into 
the plate wells. No significant differences were observed between 786-O-shcontrol and 
786-O-shKIM-1 cells in the migration assay (Figure 4A). 786-O-shcontrol cells displayed 
significantly fewer number of invaded cells compared with 786-O-shKIM-1 cell in the 
SFM group (42 vs. 98; p = 0.0006) and in the 10% group (22 vs. 36.7; p = 0.0396) (Figure 
4B). Together, these data indicate that KIM-1 expression inhibits the invasion of 786-O 
cells in vitro.  
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Figure 4. Transwell migration and invasion assay of 786-O-shcontrol and 786-O-
shKIM-1 cells. 
 (A) Migration assay of 786-O-shcontrol (KIM-1+) and 786-O-shKIM-1 (KIM-1neg) cells 
(n=3) (B) Invasion assay of 786-O-shcontrol (KIM-1+) and 786-O-shKIM-1 (KIM-1neg) 
cells (n=3). (C) Images of migration assay Transwell insert membranes. (D) Images of 
invasion assay Transwell insert membranes. 1 x 105 786-O cells were seeded in serum-
free DMEM media in Transwell inserts on top of wells filled with serum-free or complete 
DMEM media supplemented with 10% FBS. Plates were incubated at 37⁰ C for 24h. 
Transwell insert membranes for invasion assay were coated with Matrigel 12h prior to 
seeding. Data is represented as mean number of cells ± SEM (B; SFM, p = 0.0006; 10%, 
p = 0.0396, Unpaired two-tailed t-test). SFM, serum-free media; 10%, complete DMEM 
media supplemented with 10% FBS. 
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3.3 Kim-1 expression decreases cancer cell extravasation 
efficiency of murine Renca cells 
To determine the ability of cancer cells to extravasate out of capillaries, fluorescently 
labeled Renca cells were injected into the vein in the CAM of a day 13 chick embryo. An 
image of a chick embryo on day 13 reveals the tumor cell injection site and two filter square 
windows, in which cells were counted at T = 0 h and T = 24 h using a fluorescent 
microscope (Figure 5A). Figure 5B contains a typical confocal image of the fluorescently 
labeled components of the vasculature (endothelial walls and vessel lumen space) with 
Renca cells labeled in green to depict intravascular and extravasated cells. Intravascular 
cells had an irregular morphology and were retained within the blood vessel (top panel), 
whereas extravasated cells had a rounded morphology and appeared to be present in the 
extracellular stroma (lower panel) (Figure 5B).  Kim-1+ Renca cells had an extravasation 
efficiency of 47.78% which was significantly decreased compared to Kim-1neg Renca 
control cells, which had an extravasation efficiency of 60.73% (n = 6; p <0.05) (Figure 
5C). Overall, Kim-1 expression appears to decrease extravasation efficiency of the murine 
Renca cell line. 
3.4 KIM-1 expression decreases cancer cell extravasation 
efficiency of human 769-P cells 
Fluorescently labeled human RCC (769-P) cells stably expressing shRNA targeting KIM-
1 or control shRNA were injected into the vein in the CAM of a day 13 chick embryo. 769-
P-shcontrol cells had an extravasation efficiency of 30.08% which was significantly 
decreased compared to 769-P-shKIM-1 cells, which had an extravasation efficiency of 
47.94% (n = 6; p < 0.0001) (Figure 5C). These data appear to indicate KIM-1 expression 
decreases extravasation efficiency of human 786-O cells. 
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Figure 5. Chick chorioallantoic membrane (CAM) extravasation assay of 769-P and 
Renca cells. 
 (A) Image of chick embryo with representative location of tumour cell injections (needle) 
and filter square windows (white arrows). (B) CAMs used for confocal imaging were 
injected with fluorescent dyes to label the endothelial walls (purple) and the vessel lumen 
space (red), in addition to the fluorescently labeled cells (green). (C) 0.5 x 105   769-P 
(shcontrol/KIM-1+ and shKIM-1/KIM-1neg) and Renca (Kim-1+ and Kim-1neg) cells were 
injected into the vein in the CAM of a day 13 chick embryo (n = 6/ group). Two filter 
square windows were placed at sites on the CAM that were away from the injection site. 
Fluorescent cells were counted in the windows at T = 0 h and T = 24 h using a fluorescent 
microscope. Scale bar is 20 μm. Data is represented as mean of extravasation efficiency in 
percentage per group ± SEM (769-P, p < 0.001; Renca cells, p < 0.05, Unpaired two-tailed 
t-test). CAM, chorioallantoic membrane. *Methods and data adapted from Marie 
Sarabusky. 
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3.5 KIM-1 expression on Renca cells inhibits metastasis in 
an in vivo experimental metastasis model 
To investigate the role of Kim-1 expression in the metastasis of Renca cells, we injected 5 
x 105 Kim-1+ Renca or Kim-1neg Renca cells intravenously via the tail vein into 6-10-week-
old female WT BALB/c mice. In this experimental metastasis model, intravenously 
injected cancer cells invaded the lung tissue and developed metastatic nodules (Gomez-
Cuadrado, Tracey et al. 2017). Mice were sacrificed after 17 days (or if moribund), and 
their lungs were excised for examination of metastatic nodules following staining with 15% 
India black ink and Fekete’s solution. Mice injected with Kim-1+ Renca cells developed 
significantly fewer lung nodules compared to mice injected with Kim-1neg Renca cells (n = 
5; 256.6 vs. 429.4, p = 0.0226) (Figure 6). These data demonstrate that Kim-1-expressing 
Renca cells inhibit the development of lung metastases in an experimental metastasis 
model. 
 
Figure 6. Kim-1 expression on Renca cells decreases experimental lung metastases in 
WT BALB/c mice 
Approximately 5 x 105 Renca (Kim-1+ and Kim-1neg) cells were injected into 6-10-week-
old female WT BALB/c mice via lateral tail vein (n = 5/ group). Mice were sacrificed in 
CO2 chambers after 17 days. Lungs were removed, stained with 15% India black ink and 
counterstained with Fekete’s solution to visualize metastatic tumour tissue. Data is 
represented as mean number of metastatic nodules ± SEM (p = 0.0226, Unpaired two-tailed 
test). WT, wild-type. 
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3.6 Kim-1 expression does not alter the metastatic potential 
of Renca cells in an in vivo spontaneous metastasis 
model 
We injected 2 x 105 Kim-1+ Renca or Kim-1neg Renca cells orthotopically into the 
subcapsular space of the kidney of 8-12-week-old female WT BALB/c mice to investigate 
the effect of Kim-1 expression on Renca cell metastasis in a clinically relevant spontaneous 
metastasis model. No statistically significant differences were found between Kim-1+ and 
Kim-1neg cells at day 17 (Figure 7). The majority of injections yielded < 12 metastatic 
nodules, therefore, meaningful results could not be determined.  
 
Figure 7. Kim-1 expression on Renca cells has no effect on the development of 
spontaneous lung metastases. 
Approximately 2 x 105 Renca (Kim-1+ and Kim-1neg) cells were injected into the 
subcapsular space of the kidney of 8-12-week-old female WT BALB/c mice (n = 4/ group). 
Mice were sacrificed in CO2 chambers after 17 days. Lungs were removed, stained with 
15% India black ink and counterstained with Fekete’s solution to visualize metastatic 
tumour tissue. Data is represented as mean number of metastatic nodules ± SEM. WT, 
wild-type. 
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3.7 Kim-1 expression on Renca cells inhibits metastasis in 
vivo independent of adaptive immunity 
To determine whether the observed Kim-1-mediated inhibition of metastasis was 
dependent on the adaptive immune system, we repeated the above described experimental 
metastasis model using immune-deficient BALB/c (Rag1-/-) mice as hosts instead of 
immune competent (WT) BALB/c mice. As described previously, 5 x 105 Renca cells were 
injected via the lateral tail vein of Rag1-deficient BALB/c mice. Mice injected with Kim-
1+ Renca cells developed significantly fewer metastatic nodules than mice injected with 
Kim-1neg Renca cells (n = 5; 33.2 vs. 135.4, p = 0.036) (Figure 8A). These data show that 
Kim-1 decreases metastasis to the lungs in Renca cells independent of adaptive immunity.  
3.8 KIM-1 expression on 786-O cells inhibits metastasis in 
vivo independent of adaptive immunity  
To study the effect of KIM-1 expression on the metastasis of human cells, the above 
experiment was repeated with 786-O cells rather than Renca cells. Mice injected with 786-
O-shcontrol cells developed significantly fewer metastatic nodules than mice injected with 
786-O-shKIM-1 cells (n = 4 & 5; 130.6 vs. 339.3, p = 0.0013) (Figure 8B). Overall, these 
data indicate that KIM-1 expression in 786-O cells inhibits metastasis independent of the 
adaptive immune system.  
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Figure 8. KIM-1 expression on Renca and 786-O cells decreases experimental lung 
metastases in Rag1-deficient mice 
(A) Lung metastatic nodules from mice injected with Renca cells (n = 5). (B) Lung 
metastatic nodules from mice injected with 786-O cells (n = 4 & 5). 5 x 105 Renca (Kim-
1+ and Kim-1neg) and 786-O (KIM-1+ and KIM-1neg) cells were injected into 6-10-week-
old female immune-deficient Rag1-/- mice via lateral tail vein. Mice were sacrificed in CO2 
chambers after 17 days. Lungs were removed, stained with 15% India black ink and 
counterstained with Fekete’s solution to visualize metastatic tumour tissue. Data is 
represented as mean number of metastatic nodules ± SEM (Renca, p = 0.036; 786-O, p = 
0.0013, Unpaired two-tailed test). 
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3.9 RNA-sequencing of Renca cell lines to elucidate the 
mechanism of KIM-1-dependent inhibition of metastasis 
In an attempt to identify a putative mechanism to explain how KIM-1 may be inhibiting 
metastasis in RCC cells, we performed RNA-sequencing to study the differential 
expressions of genes and gene pathways between Kim-1+ Renca or Kim-1neg Renca cells 
(Figure 9). Analysis of the RNA-seq data using broad pathway filtration techniques helped 
determine gene pathways which displayed significant differences between the two cell 
lines (Table 2). Stringency values were set to only include pathways with a p-value < 0.05. 
When analyzing the data for differences in specific genes between Kim-1+ Renca or Kim-
1neg Renca cell lines, we determined a list of genes and the fold-change differences of Kim-
1+ cells relative to Kim-1neg cells (Table 3). The stringency values were set to only include 
p-values < 0.05 and exclude fold-changes between -1.5 to +1.5. The highlighted pathway 
and gene in each table were scrutinized further and found to possess functions relevant to 
invasion and metastasis.  
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Figure 9. Heatmap of genes upregulated or downregulated by Kim-1 expression in 
Renca cells. 
Heatmap of genes differentially expressed between Kim-1+ and Kim-1neg Renca cells 
generated through RNA sequencing. Only genes with significant differences (p < 0.05) are 
shown. Genes with fold-changes between -1.5 and +1.5 were excluded. Gene names are 
aligned along the left and gene clustering is shown on the right. Sample names are labelled 
along the bottom. Red represents upregulated genes. Green represents downregulated 
genes. Black represents unchanged expression. 
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Table 1: Mouse and human oligonucleotide PCR primer sequences 
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Table 2: Gene set enrichment and pathway analysis with significant differences 
between Kim-1+ and Kim-1neg Renca cell lines. 
* Pathway highlighted in yellow was determined to be the most relevant to invasion and 
metastasis and will be investigated further 
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Table 3: Genes with significant fold-change differences between Kim-1+ and Kim-1neg 
Renca cell lines. 
* Gene highlighted in yellow was determined to be the most relevant to invasion and 
metastasis and will be investigated further 
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Chapter 4  
4 Discussion 
4.1 Major Findings 
4.1.1 KIM-1 inhibits invasion of Renca and 786-O cells in vitro 
Overall, our in vitro studies suggest KIM-1 inhibits the invasive potential of RCC cells. In 
the migration assay, Kim-1+ Renca cells migrated far less than their Kim-1neg Renca 
counterparts both in the presence and absence of complete media with 10% FBS (Figure 
3A). However, there appears to have been greater numbers of migrated cells in the FBS 
group compared with the SFM group. From the Renca invasion assay, the addition of FBS 
did not appear to elicit any differences in migration (Figure 3B). This may be due to the 
fact that Matrigel contains many proteins and growth factors such as collagen IV, laminin, 
epidermal growth factor, fibroblast growth factor, and TGF-β, among many others 
(Hughes, Postovit et al. 2010). The abundance of these growth factors could potentially 
diminish the chemotactic effect of the FBS medium in the plate wells. 
In contrast, there were no observed differences in the number of migrated cells between 
786-O shcontrol and 786-O shKIM-1 in the migration assay (Figure 4A). Similar to the 
Renca migration assay however, the FBS chemoattractant group had increased numbers of 
migrated cells. Interestingly, in the invasion assay, significantly fewer 786-O shcontrol 
cells invaded compared with the 786-O shKIM-1 cells in both the SFM group and the FBS 
group (Figure 4B). These results were unexpected as we predicted that both the migration 
and invasion assays would reflect what was observed in the Renca cells. We also expected 
the FBS group to elicit a greater chemotactic response compared with the SFM group. A 
possible explanation for the difference observed between the SFM group and the 10% 
group is that the calf serum used exerts inhibitory effects on the invasive potential of human 
786-O cells in the presence of matrix proteins. In contrast to our experiment design, others 
used FBS containing media only when performing 786-O cell invasion assays (Chang, 
Chen et al. 2011, Zhao, Luo et al. 2015). Overall, our data has led us to conclude that KIM-
1 expression on Renca and 786-O cells inhibits invasion in vitro. This conclusion is 
consistent with what had been reported by Cuadros et al. who showed that 786-O cells with 
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enhanced KIM-1 shedding results in increased invasiveness in vitro (Cuadros, Trilla et al. 
2013).  
4.1.2 KIM-1 expression inhibits the extravasation of RCC cells out 
of the capillaries 
Our CAM experiments demonstrated that KIM-1 expression significantly inhibited the 
extravasation of RCC cells (Figure 5). In both human 769-P cells and murine Renca cells, 
the KIM-1-expressing group showed reduced extravasation capabilities. Our results here, 
however, contradict findings from a recent study demonstrating that KIM-1 overexpression 
in 769-P cells resulted in increased proliferation but showed mixed results in terms of 
migration (Cuadros, Trilla et al. 2014). The study found that migration in KIM-1 
overexpressing cells was delayed at early time points but proceeded to migrate faster than 
control cells at later time points. Our results clearly demonstrate that KIM-1 inhibits the 
invasive potential of 769-P and Renca cells in an in vivo model, and suggests an inhibitory 
role for KIM-1 in cancer cell extravasation.  
4.1.3 Longer time points are required for spontaneous metastasis 
models 
Our data from the pilot spontaneous metastasis experiment were inconclusive as there were 
no significant differences between the Kim-1+ and Kim-1neg groups (Figure 7). In both 
groups (n=4), only one mouse developed meaningful counts of metastatic nodules. Our 
lack of results is likely due to insufficient time for metastases to develop post-injection as 
well as decreased tumour load. We followed the protocol described by Feldman et. al. 
(2016) who also studied renal metastases to the lungs by Renca cells in mice given regular 
or high-salt diets (Feldman, Ding et al. 2016), however, we injected 2 x 105 cells instead 
of 2.5 x 105 cells. In their study, Feldman et al. sacrificed the mice 14 days after Renca cell 
implantation into the subcapsular space of the kidneys. Injection into the subcapsular space 
is a commonly accepted method for assessing renal metastasis and has been found to be 
the most advantageous site for RCC implantation (Naito, von Eschenbach et al. 1986, 
Matin, Sharma et al. 2010). A recent study injected RCC cells directly into the kidney, but 
extended the end-point to 23 days before harvesting the lungs (Murphy, James et al. 2017). 
This study also proposed the use of luciferase-expressing Renca cells so that 
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bioluminescent imaging (BLI) could be used to visualize and quantify the growth and 
spread of cancer cells. We have generated luciferase-expressing Renca cells in our 
laboratory to repeat these experiments so that we can utilize BLI.  
4.1.4 KIM-1-mediated inhibition of metastasis occurs independent 
of adaptive immunity  
Using a murine experimental metastasis model, we showed that Kim-1 expression on 
Renca cells inhibited metastasis of cancer cells to the lungs (Figure 6). Our experimental 
metastasis data suggest that Kim-1 expression inhibits mechanisms involved in the arrest 
and extravasation of Renca cells out of the vasculature and into the lungs. When we 
repeated the experimental metastasis model in immune-deficient (Rag1-/- BALB/c) mice, 
we found that the differences between KIM-1 expression persisted in the absence of an 
adaptive immune system in these mice. KIM-1+ RCC cells developed significantly fewer 
metastatic lung nodules compared with KIM-1neg cells in both the murine (Renca) and 
human (786-O) models, demonstrating that KIM-1 expression results in decreased 
metastatic potential (Figure 8). Our data indicate that the KIM-1-mediated inhibition of 
metastasis is inherent to the cancer cells themselves, and not a by-product of the adaptive 
immune system targeting KIM-1+ cells in a more efficient way. Thus, the metastatic 
phenotype is driven by a loss of KIM-1 expression in RCC cells.  
Our lab demonstrated that during renal ischemia-reperfusion injury and phagocytosis, 
KIM-1 binds to Gα12 and suppresses its activity (Ismail, Zhang et al. 2015, Ismail, Zhang 
et al. 2016). Gα12 has been demonstrated to promote proliferation and metastasis in RCC 
through various pathways (Lee, Yang et al. 2009, Hashimoto, Mikami et al. 2016). GTP-
bound-Gα12 can bind to EFA6, which can go on to activate the Arf6-EFA6 pathway 
resulting in EMT (Hashimoto, Mikami et al. 2016). Gα12 has also been shown to promote 
the expression of TGF-β1 through a Rho/Rac-dependent pathway, which ultimately leads 
to the induction of invasion and EMT (Lee, Yang et al. 2009). Rho-GTPases are 
downstream effectors of Gα12 and are crucial to the processes of actin remodeling and 
invasion (Braga, Del Maschio et al. 1999, Lozano, Betson et al. 2003, Miles, Pruitt et al. 
2008). Findings made by Ismail et. al. regarding Gα12 have implications for metastasis in 
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RCC. For instance, the inhibition of Gα12 by KIM-1 would result in the inhibition of 
downstream Rho, which results in the inhibition of invasive properties in tumour cells.   
Our current findings regarding KIM-1 in RCC contrast that of several groups who have 
claimed that KIM-1 promotes tumour growth and exacerbates cancer progression. 
Microvascular invasion (MVI) is defined by the invasion of cancer cells into the endothelial 
walls of small blood vessels and is associated with higher risks of metastases and death in 
patients with ccRCC (Eisenberg, Cheville et al. 2013, Santiago-Agredano, Alvarez-
Kindelan et al. 2013). Mijuskovic et. al. (2018) showed that high degrees of MVI were 
associated with significantly increased expression of tumour tissue KIM-1, and that urinary 
KIM-1 was associated with worse disease prognoses and higher TNM staging (Mijuskovic, 
Stanojevic et al. 2018). Their study therefore suggests that KIM-1 is associated with greater 
risks of invasion and metastases in patients with ccRCC. A recent study has also suggested 
that KIM-1 silencing in 786-O cells results in tumour growth inhibition (Xu, Sun et al. 
2018). Xu et al. found that silencing KIM-1 decreased proliferation in vitro and in vivo, 
suggesting KIM-1 is tumourigenic. In this study, KIM-1-knocked-down 786-O cells 
injected into nude mice developed smaller tumours compared with control 786-O cells – 
which endogenously expressed KIM-1.  
4.1.5 KIM-1 as a tumourigenic molecule 
Multiple studies have also identified KIM-1 as a possible early biomarker for the detection 
of clear cell and papillary RCC, and associated its expression with the disease’s tumour 
grade (Han, Alinani et al. 2005, Zhang, Mashni et al. 2014, Mijuskovic, Stanojevic et al. 
2018). One study demonstrated an association between urinary KIM-1 and tumour KIM-
1, suggesting that high levels of urinary KIM-1 are indicative of worse prognosis and 
higher tumour-node-metastasis (TNM) grades (Mijuskovic, Stanojevic et al. 2018). The 
same study demonstrated that urinary KIM-1 levels were significantly reduced post-
nephrectomy, again suggesting a link between urinary KIM-1 and disease progression. 
Another study found that KIM-1 was expressed on the majority of clear cell, papillary, and 
metastatic RCC tumours, and may serve as a diagnostic marker for these renal cancers (Lin, 
Zhang et al. 2007). It has also been previously shown that KIM-1 expression in human 
769-P cells promotes tumour growth through the activation of the IL-6/STAT3/HIF-1α 
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axis, and the silencing of the gene results in reduced proliferation and angiogenesis 
(Cuadros, Trilla et al. 2014). Studies have demonstrated that KIM-1 promotes 
tumourigenesis by increasing the secretion of tumour-promoting factors such as TGF-β and 
IL-6 (Bostrom, Lindgren et al. 2013, Sabbiseti 2014). Elevated TGF-β expression has been 
associated with the loss of VHL, and has been implicated in the processes of invasion and 
EMT (Bostrom, Lindgren et al. 2013). Furthermore, it is well established that the majority 
of ccRCC have a loss-of-function mutation in the VHL gene, which leads to the 
accumulation of HIF and the subsequent increase in VEGF and other angiogenic factors 
(De, Otterstatter et al. 2014, Kumar and Gabrilovich 2014, Schodel, Grampp et al. 2016). 
Taken together, our findings about the role of KIM-1 in RCC pathogenesis are in stark 
contrast with what had been suggested to be the role of KIM-1 in RCC. Although these 
studies appear to contradict our findings, they merely focus on a different side of the same 
coin. The studies focused on the proliferation and progression of the primary tumour as 
well as the overall disease, but our data assessed the metastatic aspect of the disease and 
suggests a role for KIM-1 in regulating the metastatic cascade. 
4.1.6 Rap1 and Rab27B may be regulated by KIM-1 
In this study, we wanted to elucidate the mechanism by which KIM-1 inhibits metastasis 
in RCC. Utilizing RNA-sequencing, we were able to determine genes and pathways that 
are differentially expressed between Kim-1+ and Kim-1neg Renca cells (Figure 9). Analysis 
of the data through the Partek Flow software allowed us to narrow down genes and 
pathways that were significantly different between the cell types. We set stringency values 
to only include p-values < 0.05. The list of significantly different gene pathways is shown 
in Table 2. From the gene pathways, we found that the Rap1 signaling pathway is highly 
involved in the processes of invasion and metastasis (Caron 2003, Shah, Brock et al. 2019). 
Rap1 is a small GTPase part of the Ras protein family and serves as a regulator of cellular 
functions such as adhesion, and integrin activation (Zhang, Wang et al. 2017). Rap1 has 
also been implicated in regulating cadherin-mediated adhesion between endothelial cells 
to form adherens junctions and strengthen cell attachment (Pannekoek, Kooistra et al. 
2009). It has been suggested that Rap1 antagonizes Ras-mediated proliferation and 
transformation independently via its complex signaling pathway. Rap1 exhibits pleiotropic 
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effects in different cancers, exerting oncogenic effects in melanoma, breast cancer, and B-
cell lymphomas (Gao, Feng et al. 2006, Lin, Tan et al. 2010, McSherry, Brennan et al. 
2011), and tumour suppressor effects in bladder, lung, and brain cancers (Lyle, 
Raaijmakers et al. 2008, Zhang, Wang et al. 2017). The regulation of adherens junctions 
and actin remodeling by Rap1 have implicated it in the progression of metastasis. Rap1-
GAP (GTPase-activating proteins) is known to inactivate Rap1 by converting GTP-bound 
Rap1 to GDP-bound Rap1 (Kim, Gersey et al. 2012). Evidence suggests that Rap1 
promotes invasion and metastasis in RCC, and Rap1-GAP is downregulated in RCC. In 
contrast, another study demonstrated that Rap1-GAP levels vary between human RCC cell 
lines, and is moderately expressed in 786-O cell lines relative to 6 other RCC cell lines, 
suggesting that 786-O cells are relatively less invasive (Wu, Zhang et al. 2011). Taken 
together, we have speculated a role for Rap1 in the invasion and metastasis of Renca cells 
which should be further explored to determine whether it is upregulated or downregulated, 
and whether the metastatic phenotype in Kim-1neg cells is due to upstream effects of Kim-
1 on the Rap1 pathway. 
When we analyzed the RNA-seq data for specific genes that had significant fold-changes 
between Kim-1+ and Kim-1neg Renca cells, we found that Rab27B displayed a significant 
decrease in fold-change in Kim-1+ cells compared with Kim-1neg cells (Table 3). Like 
Rap1, Rab27B is a member of the Ras-family of GTPases, and has been shown to be 
involved in proliferation and invasion in several cancers, with their downregulation 
conferring reduced invasiveness and improved prognoses (Li, Jin et al. 2017, Yang, Ye et 
al. 2017, Wu, Niu et al. 2019). In lung adenocarcinoma studies, Rab27B expression was 
significantly higher in cancer cells compared with noncancerous cell lines, and has been 
suggested as a negative prognostic marker for lymph node metastasis and TNM staging 
(Zhang, Fan et al. 2018). Studies have suggested that Rab27B regulates the 
phosphatidylinositol 3 kinase (PI3K)/AKT pathway in hepatocellular carcinoma (Yang, Ye 
et al. 2017). The PI3K/AKT pathway has been shown to regulate multiple aspects of cancer 
including metastasis (Manning and Cantley 2007), and has also been implicated in RCC 
and is known to be highly activated in the disease (Guo, German et al. 2015). Interestingly, 
a recent study investigated Rab27A and Rab27B (the 2 subunits of Rab27) and 
demonstrated that Rab27A – but not Rab27B – was significantly associated with TNM 
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staging and could serve as a potential prognostic marker for RCC (An, Song et al. 2019). 
In context with our findings, another possible mechanism could be that Kim-1 
downregulates Rab27B, resulting in decreased proliferation and invasion of Renca cells. 
The role of Rab27B in RCC is unclear, but it may serve as a promising target to focus 
future research on. 
4.2 Limitations 
4.2.1 Transwell migration and invasion assays 
Transwell chemo-invasion assays were developed over two decades ago and continue to 
serve as a quick and quantitative model to study invasive cell migration and cell 
interactions with basement membranes (Albini and Noonan 2010). It remains a relevant 
model for investigating cancer cell invasiveness in vitro as it has been demonstrated that 
only tumourigenic cells are able to penetrate Matrigel layers (Albini and Noonan 2010, 
Hughes, Postovit et al. 2010). Serum-free media was used in these pilot experiments to 
assess the baseline migration of the cells relative to FBS – a standard chemotactic agent in 
Transwell assays. Fetal bovine serum is one of the most well-known and widely used 
serums, and contains a multitude of macromolecules, nutrients, attachment and 
dissemination factors, as well as hormones and growth factors (Shah 1999, Gstraunthaler 
2003). It is often used as a supplement in cell culture, and as a chemotactic agent in 
migration and invasion assays for RCC (Liu, Zhang et al. 2016, Huang, Wei et al. 2017). 
This is in line with the standard method found in the literature, which typically uses FBS 
containing medium as the chemoattractant in the plate wells. Additionally, SFM controls 
are not typically necessary for migration and invasion assays. To elicit more profound and 
physiologically relevant responses, the addition of chemokines or conditioned media is 
sometimes used in place of FBS (Justus, Leffler et al. 2014, Jeong, Han et al. 2016, 
Gabrielyan, Neumann et al. 2017). It has been reported that media conditioned from 
fibroblasts or cells of choice contribute cytokines, growth factors, metabolites, and ECM 
proteins to the media, which offer greater growth and chemotactic capacities for cells 
(Jeong, Han et al. 2016). Alternatively, some studies stimulate cells with chemokines or 
engineer chemokine overexpression prior to seeding in the Transwell insert to upregulate 
migratory processes (Xuan, Feng et al. 2017, Zhuang, Cao et al. 2018). 
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A major limitation of the Transwell assay as a method to study extravasation is that it is 
only an in vitro model and can only investigate the invasiveness of cancer cells at the 
Matrigel interface. As such, it only simulates 2D interactions between cancer cells and the 
Matrigel over circular pores and offers a limited scope of what occurs in 3D at tight 
endothelial junctions in vivo during arrest (Kim, Williams et al. 2016). Additionally, the 
effect of hemodynamics and plasma proteins on migrating cells cannot be investigated 
using this model as the in vitro model lacks the full repertoire of cell types present in the 
blood. Another limitation is that the time points set for incubation are arbitrary and are not 
representative of the invasion process in vivo which is not as forgiving if cells fail to 
migrate across the endothelium.  
4.2.2 CAM extravasation assay 
The CAM extravasation assay overcame the limitations of the Transwell assay by 
providing a rapid and quantitative assessment of extravasation in an in vivo model. The 
assay was conducted by Marie Sarabusky, who followed the protocol for the CAM 
extravasation model as described (Kim, Williams et al. 2016). The assay allowed us to 
specifically investigate the ability of cancer cells to arrest and extravasate out of capillaries 
into surrounding tissues. It also allowed us to visualize the process of extravasation by 
using fluorescent dyes to label the cells and the vasculature. Additionally, the low cost of 
this assay allowed for greater sample sizes with adequate power and allowed for the valid 
determination of statistical significance.  
However, a limitation of the CAM assay is that the use of fluorescently labelled cells – a 
technique that requires relatively more complex and expensive equipment – is fundamental 
for visualizing the extravasation of cancer cells from the blood vessels (Kim, Williams et 
al. 2016). Another limitation to consider is the fact that this model was designed to 
investigate extravasation of mammalian cells but is applied in an avian embryo. Certain 
plasma proteins, hormones, and growth factors specific to mammalian cells may not be 
present in this model. There may not be a complete repertoire of human and mouse 
accessory proteins and growth factors in the chicken embryo, which could have potentially 
modulated the phenotypes we observed. Finally, expertise with IV injections is a necessity 
for the implantation procedure. 
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4.2.3 Experimental metastasis model 
The in vivo experimental metastasis model is a relevant model to investigate metastasis and 
the interaction of molecules with the endothelium of blood vessels (Gomez-Cuadrado, 
Tracey et al. 2017). The use of this experimental metastasis model allowed us to 
specifically study the late stages of the metastatic cascade: the arrest and extravasation of 
cancer cells into the lungs. Renal cell carcinoma preferentially metastasizes to the lungs, 
so this model was relevant in understanding the effect of KIM-1 expression during 
extravasation.  
A major limitation of the experimental metastasis assay (the IV tail injection model 
specifically) when it comes to studying metastasis is that it only recapitulates the late stages 
of the metastatic cascade; arrest and extravasation out of the capillaries into the lungs 
(Gomez-Cuadrado, Tracey et al. 2017). This assay evaluates how cancer cells grow in 
ectopic sites but cannot account for how the primary tumour develops and invades into the 
vasculature.  
4.2.4 Spontaneous metastasis model 
The spontaneous metastasis model implants the cancer cells orthotopically and overcomes 
some of the limitations of the experimental model. It mimics the human disease and allows 
for the development of the primary tumour and its dissemination to secondary sites 
(Gomez-Cuadrado, Tracey et al. 2017). However, a drawback is that the earliest steps of 
tumour formation cannot be assessed as the tumours do not spontaneously arise. Transgenic 
mice allow for the autochthonous development of tumours which recapitulate the entire 
metastatic cascade and allow for the study of cancer progression using experimental 
models (Kabeer, Beverly et al. 2016, Gomez-Cuadrado, Tracey et al. 2017). For example, 
mice engineered with a mutant p53 gene develop normally but are prone to spontaneous 
tumour formation (Donehower, Harvey et al. 1992). Alternative methods utilize the Cre 
recombinase/lox P system to activate specific oncogenes or inactivate specific tumour 
suppressors and control the timing for tumour initiation (Jackson, Willis et al. 2001, 
Gomez-Cuadrado, Tracey et al. 2017). Lox P recombination sites flank genes of interest 
through homologous recombination, which can then be excised when the Cre recombinase 
54 
 
 
is activated (Gu, Zou et al. 1993). A second limitation is that murine kidneys are quite 
small, so expertise is required when injecting the cells under the subcapsular space to avoid 
leakage of cells under the capsule or out of the kidneys. Furthermore, it is impossible to 
measure the growth of the primary tumour using typical caliper measurements, so BLI will 
have to be used to quantify tumour growth and dissemination via fluorescent protein signal 
intensity.    
4.2.5 Rag1-/- mice in an experimental metastasis model 
Rag1-/- mice lack a functional recombination activation gene (RAG), which prevents them 
from activating V(D)J recombination early on during T and B cell development 
(Mombaerts, Iacomini et al. 1992). This recombination is critical to the differentiation of 
T and B cells, and a deficiency results in mice that have underdeveloped lymphoid organs 
which lack mature T and B lymphocytes. These mutant mice lack a functional adaptive 
immune system, thus any observed differences in phenotype can be attributed to KIM-1 
expression, and not adaptive immunity.  
A major limitation of using Rag1-/- mice is that it knocks out the adaptive immune system 
(T and B cells) but have an intact natural killer (NK) cell population. NK cells are 
classically considered innate cells and thought to be activated in response to missing MHC 
class I molecules on virus-infected or cancer cells, and induce adaptive immune cell 
activation (Vivier, Tomasello et al. 2008). It has been suggested that NK cells possess anti-
tumour properties and inhibit tumour growth and progression early on through various 
pathways including Fas ligand and granzyme-family proteases. Some studies have shown 
however, that although NK cells are still present in Rag1-deficient mice, Rag proteins are 
essential for the functional development and survival of NK cells (Andrews and Smyth 
2010, Karo, Schatz et al. 2014). Thus, the Rag1-/- mouse model serves its purpose of 
studying the effect of the adaptive immune system in KIM-1-mediated inhibition of 
metastasis. An alternative method would be to perform T and B cell depletion to verify that 
the observed phenotypes are indeed a result of KIM-1 expression, rather than the adaptive 
immune system.  
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4.3 Future Directions and Significance 
The implications of our findings within the context of the known literature suggests that 
KIM-1 expression within tumours may have a paradoxical effect between tumour growth 
and metastatic ability. On one hand, KIM-1 expression in the tumour promotes 
proliferation and angiogenesis. On the other hand, KIM-1 expression inhibits the metastasis 
of the primary tumour cells to distant organs. Although the literature predominantly points 
towards KIM-1 as tumourigenic, there is evidence to support our data and reconcile the 
two sides of the coin. A study by Cuadros et. al. (2013) investigated the effect of KIM-1 
ectodomain shedding on the invasive capacity of 786-O cells and found that increased 
shedding ability was directly associated with increased invasiveness and tumour 
malignancy (Cuadros, Trilla et al. 2013). Their results suggest that surface expression of 
KIM-1 inhibits invasive properties of RCC cells. An earlier study by Guo et. al. (2012) 
engineered HT1080 cells that expressed KIM-1, or KIM-1 with a mutated juxtamembrane 
region which was resistant to shedding by membrane-type-1 matrix metalloprotease (MT1-
MMP) (Guo, Takino et al. 2012). They found that the HT1080/KIM-1 cells had their KIM-
1 actively cleaved by MT1-MMP, which resulted in significantly increased cell adhesion, 
invasive growth, and metastasis compared with HT1080/ΔKIM-1 cells. Together with 
these studies, our work may pave the way for a new hypothesis: although KIM-1 
exacerbates tumour growth and progression, the active cleavage of KIM-1 may allow 
disseminated cancer cells to arrest and invade secondary tissues more efficiently. KIM-1 
is overexpressed in >90% of RCC tumours and over a third of patients present with 
metastases – the primary cause of death in patients with RCC – at the time of diagnosis 
(Canadian Cancer Society 2015). These facts coupled with our data that indicates KIM-1 
inhibits metastasis suggest that KIM-1 is potentially cleaved off RCC cells during their 
dissemination into the vasculature.  
Future work will be aimed at optimizing the spontaneous metastasis model and using 
Renca-Luciferase cell lines to visualize and quantify tumour growth and metastatic spread 
via BLI. Optimizing the spontaneous metastasis model will allow us to determine whether 
the observed phenotypes in the experimental metastasis model are consistently expressed. 
It will also illuminate whether Kim-1 on RCC cells is shed during its dissemination to the 
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lungs in a mouse model. We will also explore the effect of anti-Kim-1 antibodies on the 
development of metastatic lung nodules within both the experimental and spontaneous 
metastasis model to determine whether blocking Kim-1 in mice injected with Kim-1+ cells 
will abrogate Kim-1-mediated inhibition of metastasis. Furthermore, Rap1 and Rab27B 
will be investigated in more detail to determine whether silencing these genes in Kim-1neg 
Renca cells can block metastasis, and whether Kim-1 inhibits these GTPases like Gα12. 
Future research could help elucidate the precise mechanism of KIM-1 inhibition and 
develop specific antagonists that interact with the downstream effectors of KIM-1 in hopes 
of treating metastatic RCC in patients.  
4.4 Conclusion 
Our results represent a novel discovery which unveils new perspectives on the relationship 
between KIM-1 and RCC disease progression. In this study, we hypothesized that KIM-1 
expression on RCC cells inhibits their ability to invade and metastasize and our findings 
are supported by human clinical data (National Cancer Institute 2006). In summary, our 
work has provided a clearer understanding on the role of KIM-1 in the invasion and 
metastasis of RCC, and has ultimately provided evidence in support of our hypothesis. We 
have demonstrated that KIM-1 expression inhibits invasion of Renca and 786-O cells in 
vitro. We have highlighted the inhibitory effect of KIM-1 on the extravasation efficiency 
of Renca and 769-P cells in an in vivo CAM model. We have shown that KIM-1 expression 
inhibits metastasis in Renca and 786-O cells, and that this inhibitory effect occurs 
independently from the adaptive immune system. Additionally, we have identified two 
putative genes (Rap1 and Rab27B) involved in invasion, adhesion, and metastasis that may 
be regulated by Kim-1. Continued research on the role of KIM-1 in metastatic RCC is 
likely to substantially enhance our understanding of the pathogenesis of metastatic disease 
and lead to the development of novel therapeutic targets. The extent of the role that KIM-
1 plays in the metastatic cascade of RCC – of which has previously not been studied or 
discussed within the literature – has thus far been incompletely understood. 
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Appendices  
Appendix A 1: Overall survival between RCC patients with high or low HAVCR1 
expression based on data from TCGA RNA-seq database. 
A 
 
B 
 
Supplemental Figure 1. Overall survival between RCC patients with high or low 
HAVCR1 expression based on data from TCGA RNA-seq database. In renal cell 
carcinoma (RCC), expression of HAVCR1 is significantly upregulated in patient specimens 
but low expression of HAVCR1 is significantly associated with poor prognosis of RCC 
patients (P = 0.0034) based on data in The Cancer Genome Atlas. A) HAVCR1 mRNA 
levels in 72-paired tumour and non-tumour margin tissue specimens of RCC patients 
obtained from TCGA gene expression profiling datasets are shown. mRNA levels are 
expressed as individually in tumour vs. non-tumour for each patient. B) Kaplan-Meier 10-
years (left) or 5-years (right) overall survival curves according to lower versus higher 30% 
mRNA expression level of HAVCR1 in TCGA RCC patients.  
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Appendix A 2: Fekete's Solution 
 
 
Appendix A 3: Western blots of murine Kim-1 knock-in in the Renca cell line 
A      B 
      
Supplemental Figure 3. Western blots of murine Kim-1 knock-in in the Renca cell 
line. Renca cells, which do not endogenously express Kim-1, were transfected with either 
pCDEF3 or pCDEF3-mKim-1 plasmids. A) Protein expression in cell lysates from 
pCDEF3 and pCDEF3-mKim-1 transfected Renca cells were compared to the endogenous 
protein level of mKim-1 in primary PTECs isolated from WT C57BL/6 mice and to HEK-
293 cells transfected with the mKim-1 plasmid. B) Renca-pCDEF3 mKim-1 (2) and Renca-
pCDEF3 (2) were subjected to G418 selection (400 μg/ml) to select for stable clones 
expressing mKim-1 or the control plasmid, respectively. Protein lysates from respective 
Renca clones were compared to the endogenous protein level of Kim-1 in primary PTECs 
isolated from WT C57BL/6 mice and to HEK-293 cells transfected with the mKim-1 
plasmid. WT, wild-type; mKim-1, murine Kim-1; C57BL/6 PTECs, primary proximal 
tubular epithelial cells isolated from a WT C57BL/6 mouse following kidney injury. 
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Appendix A 4: Murine Kim-1 expression in the Renca cell line 
A           B 
  
Supplemental Figure 4. Murine Kim-1 expression in the Renca cell line. Renca cells, 
which do not endogenously express Kim-1, were transduced with either lentiviral particles 
containing the Kim-1 transcript within the vector (Renca-mKim-1) or just the vector alone 
(Renca-control) and then subjected to selection using puromycin (2 μg/ml) for generation 
of stable cell lines. A) Western blot of protein expression in lysates from Renca-mKIM-1 
cells at different MOIs and Renca-control cells (MOI of 60) were compared to the 
endogenous protein level of mKim-1 in primary PTECs isolated from WT C57BL/6 mice 
and to HEK-293 cells transfected with the pCDEF3-mKim-1 plasmid. B) mRNA 
expression levels of Kim-1 in Renca-mKim-1 and Renca-control cells transduced with a 
MOI of 60 were compared to the endogenous mRNA expression level of mKim-1 in 
primary PTECs isolated from WT C57BL/6 mice using standard PCR as described in the 
materials and methods. Normalization was performed to GAPDH. WT, wild-type; mKim-
1, murine Kim-1; MOI, multiplicity of infection; C57BL/6 PTECs, primary proximal 
tubular epithelial cells isolated from a WT C57BL/6 mouse following kidney injury. 
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Appendix A 5: Human KIM-1 knock-down in 769-P cell line 
A     B 
  
Supplemental Figure 5. Human Kim-1 knockdown in the 769-P cell line. 769-P cells, 
which endogenously express high levels of KIM-1, were transduced with either lentiviral 
particles containing KIM-1-specific constructs encoding shRNA (shKIM-1) or a scrambled 
shRNA sequence (shcontrol). A) Protein expression in cell lysates from shcontrol and 
shKIM-1 were compared to the endogenous protein expression level of KIM-1 (769-P WT) 
by western blotting using antibodies against KIM-1 (extracellular domain) and β-actin. B) 
Relative mRNA expression levels of KIM-1 from total RNA extracted from shcontrol and 
shKIM-1 cells using real time-PCR (RT-PCR) (n = 9; *** = p < 0.0001). Normalization of 
KIM-1 was performed to GAPDH and expressed as a fold change. Data is shown as mean 
± SEM in the graph. WT, wild-type; hKIM-1, human KIM-1. 
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